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Abstract 
 
Development and Validation of a Rapid Analytical Method and Sampling 
Methodology for Trace Level APIs in Support of Cleaning Validation. 
By Patricia Boyle 
 
In pharmaceutical industries, the cleaning procedure is one of the most critical 
processes. It is crucial to prove that the production equipment surfaces are consistently 
cleaned from product residues to prevent possible contamination and cross-
contamination. Therefore, the cleaning procedure must be appropriately validated and 
robust. The cleaning procedures must be supported by validated analytical methods 
and related sampling methodologies. The cleaning analytical methods and related 
sampling methodologies are critical in establishing quality validated cleaning 
programs, as they quantitatively determine the amount of residual API, if present, on 
the manufacturing equipment post-cleaning. 
The overall aim of this research was to develop a rapid liquid chromatographic 
method and related sampling methodologies which can be used to verify that 
production equipment surfaces have been cleaned to an extent that meets existing 
regulatory requirements. A High Performance Liquid Chromatographic (UPLC) 
analytical method designed to have a broad applicability for the simultaneous 
determination of a range of API residues in ophthalmic solutions was developed. The 
API residues investigated were dexamethasone fluorometholone, prednisolone, 
prednisolone acetate, ketorolac tromethamine, flurbiprofen, timolol maleate, 
levobunolol hydrochloride, brimonidine tartrate and ofloxacin. A Design of 
Experiments (DOE) approach utilising Dry Lab and Minitab software was adopted to 
facilitate rapid method development and ensure the desired resolution ( ≥ 2.0) between 
each peak pair within 15 minutes. The optimised method, using a UPLC reverse phase 
chromatographic column and gradient elution with an ammonium acetate buffer and 
acetonitrile provided the desired resolution between all the drug substances in 13 
minutes. For evaluation purposes, standard analytical performance criteria were 
examined for the developed method.  
The developed analytical method was used in combination with the developed 
sampling methodologies to ensure optimal recoveries for each API residue from the 
various product contacting surfaces. Interferences from the swab and product 
contacting surfaces that may affect the quantitation of the APIs were examined. A 
variety of swabs (polyester, cotton, etc), product contacting surfaces (steel, glass, 
silicone, and teflon), and solvents were included in this study to investigate for 
interferences and evaluate the recoveries of the APIs from the product contact surfaces. 
The TX761 polyester swab was found to provide the least amount of extractables and 
interferences which may interfere with the selected drug substances. In addition, the 
TX761 swab was shown to adequately remove the majority of the selected API 
residues from stainless steel, teflon, glass and silicone. It was shown however that 
flurbiprofen was more difficult to remove from the silicone surfaces than the other 
APIs. 
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1.1. An introduction to cleaning validation 
Since the 1990’s, cleaning validations have gained a lot of interest within 
pharmaceutical and bio-pharmaceutical companies. In 1988, the FDA experienced its 
first major incident with cross contamination traceable to inadequate cleaning and 
cleaning validation. The finished drug product, Cholestyramine Resin USP, was 
recalled due to contamination with low levels of intermediates and degradants from the 
production of agricultural pesticides. The cross-contamination was believed to have 
come from the use of drums in the production of the active pharmaceutical ingredient 
(API). These drums had previously been used to store solvents for the manufacture of 
agricultural pesticides at another plant. The drums were inadequately cleaned leading 
to low levels of the agricultural pesticides entering the API manufacturing processes. 
This incident raised the FDA’s awareness to the potential impact of cross-
contamination from un-validated cleaning processes [1, 2].
 
The U.S Food and Drug Administration (FDA) issued its Guide to Inspections 
– Validation of Cleaning Process in 1993. Previously, validation was required only for 
the manufacturing process of drug products and not for the cleaning process of the 
manufacturing equipment. The objective of cleaning validation is to prove that the 
equipment is consistently cleaned from product, detergent and microbial residues to an 
acceptable level, to prevent possible contamination and cross-contamination. The 
driving force for cleaning validation is patient safety and product quality. Cross-
contamination with residues of any kind presents a safety risk to patients consuming 
the drug product. It threatens to alter the strength, chemical identity, and integrity of 
the drug substance and formulation. For these reasons, it is essential to have a robust 
validated cleaning process that is suited to its intended purpose [1,3-7]. 
An inadequate or incomplete cleaning regime between production campaigns 
could result in trace levels of APIs remaining on the production equipment with 
obvious implications for product quality. Therefore, determining what level of API 
residue is allowed to remain on the manufacturing equipment after the cleaning 
process has taken place is a crucial part of an effective cleaning validation program. 
The maximum allowable carryover (MAC) of an API residue is determined by a 
number of factors such as the therapeutic dose of the product, the defined safety factor, 
batch sizes of the product and minimum/maximum daily doses of the product. These 
residue acceptance limits are further discussed in Section 1.2. Generally, residue 
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acceptance limits are established first, then the analytical method and related sampling 
methodologies are developed and validated to ensure that the maximum acceptable 
limits and below can be accurately quantitated.  
After a cleaning regime on manufacturing equipment surfaces post-product 
manufacture, several swabs are generally taken from different equipment surfaces 
(reactor, centrifuge, dryer, etc.) and are analysed for API residues. The analytical 
results are required as soon as possible to minimize down-time between product 
campaigns. If API residue is found above the acceptable residue carryover limit on any 
of the swabs, production would be delayed by the initiation of a further 
cleaning/rinse/analysis cycle before the next batch of product is manufactured. It is 
therefore crucial to employ rapid methods for cleaning validation activities. In 
addition, it is crucial to have an effective sampling methodology in place [1,3-7]. 
1.2. Establishing residue acceptance limits  
1.2.1. Introduction 
 An important aspect of a cleaning validation is to establish what level of API 
residue is allowed to remain on the manufacturing equipment surfaces after the 
cleaning process has been carried out post-production. This is a critical aspect as any 
residue remaining on the manufacturing equipment after cleaning will be transferred 
over into the first batch of the next pharmaceutical product as shown in Figure 1.1       
[1-7]. In the past, detection and quantitation of trace level residues was more difficult 
due to the limited analytical technologies available. Today however, there are many 
analytical technologies available such as Ultra Performance Liquid Chromatography 
(UPLC) and Mass Spectrometry (MS) that are capable of detecting and quantitating 
trace amounts of API residues that may remain on the manufacturing equipment after 
the cleaning process has been carried out.  
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Figure 1.1: Residue contamination of pharmaceutical product, taken from [4]. 
 One of the earliest articles published regarding the validation of cleaning 
procedures was by Harder in 1984. In the article, Harder discusses different aspects of 
what may be required for an effective cleaning procedure. With regards to the setting 
of residual acceptance limits, Harder wrote that limits should be practical and 
achievable using the defined cleaning procedure and that the residue acceptance limits 
should be verified by the analytical technique used by the company [2,8]. In many of 
the guidances today, it states that the establishment of residue acceptance limits must 
be practical, achievable and verifiable [1,3-6]. In 1993, an article by Fourman and 
Mullen of Eli Lilly proposed the use of the following combination of residue 
acceptance limits for cleaning validation [9]. 
 No more than 0.001 dose of any product will appear in the maximum daily 
dose of another product. 
 
 No more than 10 ppm of the product will appear in another product. 
 
 No quantity of residue will be visible on the equipment after cleaning 
procedures are performed. 
In recent years, a number of regulators have adopted this approach and have 
included these limits in their own guidance documents [3-6]. The FDA has not 
included residue acceptance limits in their guidelines due to the wide variation of 
equipment and products used from company to company. However, they do state that a 
company’s rationale for establishing residue acceptance limits should be practical, 
achievable and verifiable, and they have accepted the application of Fourman and 
Mullen’s residue acceptance limits approach as the industry norm. Rather than focus 
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on the basis for the limits, it is more important to focus on correct implementation of 
the limits [1]. 
1.2.2. Dose residue acceptance limit approach 
 Pharmaceutical companies must demonstrate that the cleaning procedures used 
for the various pieces of manufacturing equipment are effective and fit for their 
intended purpose. The cleaning procedures must show that the potential carryover of 
residue into the next product is limited, and if there is carryover, it is at an acceptable 
level. The limits established must be based on sound scientific rationale. They must 
also be practical, achievable and verifiable [1-9]. As stated in the Fourman and Mullen 
article ‘No more than 0.001 dose of any product will appear in the maximum daily 
dose of another product’. The logic behind the 0.001 (1/1000th) dose derives from three 
factors of 10 [9]. 
1. ‘Pharmaceuticals are often considered to be non-active at 0.1 of their normally 
prescribed dosages’. 
 
2. ‘A safety factor’. 
 
3. ‘The cleaning validation program should be robust, i.e. be vigorous enough that it 
would be considered acceptable for quite some time in a world with ever tightening 
standards’. 
 
This approach is provided in many of the guidances. In cases where the therapeutic 
dose in not known, the MAC may be calculated using toxicity data [3-7]. 
1.2.3. 10 ppm residue acceptance limit approach 
An alternative residue acceptance limit criterion stated in the article by 
Fourman and Mullen is that ‘No more than 10 ppm of the product will appear in 
another product’ [9]. Generally in the current guidance documents, if the limit per 
swab area calculated is above 10 ppm, then the 10 ppm residue acceptance limit 
approach is used [3-7].  
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1.2.4. Visible residue acceptance limit approach 
 The acceptance criterion stated in many of the regulatory and guidance 
documents is ‘No quantity of residue should be visible on the equipment after cleaning 
procedures are performed’ [3-6]. Before validated cleaning processes were introduced 
into pharmaceutical companies, the manufacturing equipment was always visually 
inspected before any drug manufacturing took place. Since the introduction of cleaning 
validation programs, analytical testing has been the preferred approach for establishing 
the amount of residue, if present, remaining on the manufacturing equipment surfaces 
after cleaning. However, visual inspections are still carried out in pharmaceutical 
companies as per regulations and industry guidances, but they are carried out in 
conjunction with the analytical methodologies [10-15]. 
The general approach to establishing a visible residue limit is to apply a 
standard solution containing the API residue onto a coupon that is the material 
representative of the product contacting surface, e.g. stainless steel. The level of 
residue is applied at approximately the residue limit. The coupon is dried under 
nitrogen to minimize oxidation which might alter the appearance of the dried API 
residue. The coupon with the dried API residue is then compared to the manufacturing 
equipment after the cleaning process has been completed, to establish whether the 
manufacturing equipment meets the visible residue limit criterion, as shown in Figure 
1.2 [10-15]. 
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Figure 1.2: Visual inspection of manufacturing equipment using the visual residue 
acceptance limit approach, taken from [12]. 
1.3. Analytical techniques used in support of cleaning validation  
1.3.1 Introduction 
With the analytical technologies that are available today, quantitation of API 
residues at very low levels from the manufacturing equipment is possible even after 
vigorous cleaning procedures have been carried out. The analytical cleaning methods 
that are used to quantitate API residues should be specific for the residue/residues to be 
analysed and should be sensitive enough to detect the target API. If the API residue is 
not detected using the specified analytical method, it does not necessarily mean that 
there is no residual API contamination after the cleaning process. It only means that 
levels of API residue greater than the detection limit of the analytical cleaning method 
are not present in the sample. There are many different analytical techniques available 
for cleaning validations, but selection of an appropriate analytical technique depends 
on the parameters to be measured. There are two types of analytical methods that are 
generally used for cleaning validations, specific and non-specific analytical methods 
[1,3-7]. Some examples of specific and non-specific methods are listed in Table 1.1. 
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      Table 1.1: Non-specific and specific methods used for cleaning validation. 
Non-specific Specific 
Total Organic Carbon (TOC) Liquid chromatography (LC) 
pH Ion chromatography (IC) 
Conductivity Atomic absorption (AA) 
 
1.3.2. Non-specific methods 
Non-specific analytical methods measure a general property, such as 
conductivity or total organic carbon (TOC), which may result from a variety of 
chemical species or sources. One of the most widely used non-specific analytical 
techniques for cleaning validations is TOC analysis. TOC is the amount of carbon 
found in an organic compound and is determined by the oxidation of these organic 
compounds into carbon dioxide. The oxidation can occur through a number of 
mechanisms such as UV, persulfate, and combustion. TOC is generally used for the 
analysis of water soluble drug substances, cleaning agents and excipients with regards 
to cleaning validations. The advantages of TOC are; low level detection, fast analysis 
time and low cost. However, the limitation associated with TOC analysis is that it 
cannot give exact quantitative results for the target residue, therefore making it harder 
to pass the stringent residue acceptance limit criteria [6,16-20]. The pH and 
conductivity methods are generally used for residual analysis of cleaning agents. A 
linear response between the conductometer and the ion concentration in the cleaning 
agent sample can be established, however, pH can only be used to verify qualitatively 
the presence of the correct cleaning solution [6,21]. 
1.3.3. Specific methods 
Specific methods can quantitate the exact amount of the target residue present 
in a sample in the presence of expected interferences. They can simultaneously give 
quantitative and qualitative results, and therefore they are generally the preferred 
analytical technique for analysis of API residues in support of cleaning validation 
[4,6,16,17,21]. Some examples of specific methods shown in Table 1.1 include liquid 
chromatography (LC), ion chromatography (IC) and atomic absorption (AA).  
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One of the most widely used specific analytical techniques for quantitating API 
residues from manufacturing equipment surfaces is LC. Examples of the LC 
technologies available today that have the advantage of improved speed, sensitivity 
and selectivity are liquid chromatography-mass spectrometry (LC-MS), and ultra- 
performance liquid chromatography-mass spectrometry (UPLC-MS). However, high 
performance liquid chromatography (HPLC) or UPLC methods hyphenated to MS are 
more expensive than using traditional LC detectors and are not as widespread yet in 
pharmaceutical companies for the analysis of residual APIs [4,6,16,17,21]. Ion 
chromatography is another powerful analytical technique that is used for trace analysis 
in support of cleaning validation. It is generally used for the analysis of anions and 
cations in the cleaning agents used to clean the equipment trains post-production, and 
can quantitate cleaning agent residues down to parts per million (ppm) levels [22,23]. 
Atomic absorption (AA) is typically used for metal ions and is an effective technique 
for the analysis of rinse samples with trace level quantitation down as far as parts per 
billion (ppb) levels [24,25].  
1.3.4. Overview of Ultra Performance Liquid Chromatography 
UPLC was the analytical technique chosen for this research due to its many 
desirable characteristics. Its advantages over the use of HPLC are increased resolution, 
increased speed, and increased sensitivity. HPLC typically uses stationary phases 
consisting of particle sizes from 3 to 5 µm, while UPLC uses columns with particle 
sizes of 2 µm and less. The Van Deemter plot in Figure 1.3 shows the height 
equivalent to the theoretical plate versus the linear velocity for different particle sizes. 
It shows that the higher column efficiencies were obtained when the size of the particle 
decreased. Therefore, smaller particle sizes allow for increased speed and better 
resolution between analytes. In addition, lower flow rates are used for UPLC methods. 
Therefore, there is a reduction in solvent consumption and solvent waste which makes 
UPLC both cost effective and environmentally friendly [26-28]. 
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Figure 1.3:  Van Deemter Curves for particle sizes, 1.7, 3, 5, and 10 µm, taken from 
[28]. 
1.3.5. Validation of analytical methods in support of cleaning validation  
 An important part of cleaning validation is setting residue limits and then 
measuring the residues left on the product contacting surfaces after cleaning. 
Therefore, it is critical that the analytical cleaning method is validated appropriately.  
There are generally four different types of analytical methods with varying validation 
requirements which are shown in Table 1.2. 
A cleaning method validation is typically carried out using the criteria in 
International Conference on Harmonization (ICH) guidelines Q2 (R1) for quantitative 
testing of impurities. For swab sampling, recovery studies may be performed as part of 
the analytical method validation or they may be performed as separate studies once it 
is determined that the analytical method can appropriately measure residues in 
solutions. In addition to the ICH Q2 parameters, swab sample stability as a function of 
storage conditions (time, temperature, vial for storage, etc.) may be evaluated if there 
is a significant interval between sampling and analysis [4,6,29]. 
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Table 1.2: Validation of analytical procedures [29]. 
 
Characteristic 
Type of Analytical Procedure 
 
Identification 
Testing for Impurities  
Assay Quantitative Limit 
Accuracy - + - + 
Precision     
Repeatability - + - + 
Intermediate Precision - +
1 - + 
Specificity
2
 + + + + 
Detection Limit - -3 + - 
Quantitation Limit - + - - 
Linearity - + - + 
Range - + - + 
 - Signifies that this requirement is not normally evaluated 
+ Signifies that this requirement is normally evaluated 
1 In case where reproducibility has been performed, intermediate 
   precision in not required 
2 Lack of specificity of one analytical procedure could be compensated  
   by other supporting analytical procedure(s) 
3 may be needed in some cases 
 
1.3.5.1. Validation Parameters 
1.3.5.1.1 Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present, such as impurities, degradants or the 
sample matrix [29]. The surface of a production equipment train generally consists of 
mostly stainless steel (> 95%), but there are critical surfaces, which are made of glass, 
teflon, and silicone. These critical surfaces may be hard to clean, so it is necessary to 
sample these areas during the cleaning validation process. With regards to specificity, 
interferences from the sampling procedure must be taken into account. This should 
include blank extractions of the swab material, as well as blank swabs from all the 
sampling surfaces (stainless steel, glass, teflon and silicone). Specificity is 
demonstrated by lack of interferences or sufficient resolution between the peak of 
interest and any interfering peaks from the swab or product contact surfaces        
[4,6,7,29-31]. 
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1.3.5.1.2. Linearity 
The linearity of an analytical cleaning procedure is its ability to obtain test 
results which are directly proportional to the concentration of residue in the sample. A 
minimum of 5 concentrations is measured across the range of the analytical method. 
Dilute stock standard preparations of the API residue to be quantitated may be used. 
The signals are plotted as a function of concentration. A correlation coefficient of         
≥ 0.99 is sufficient for residual cleaning analytical methods [4,6,7,29-31]. 
1.3.5.1.3. Limit of Quantitation (LOQ)  
The limit of quantitation of an analytical cleaning procedure is the lowest 
amount of residue in a sample which can be quantitatively determined with suitable 
precision and accuracy. For a cleaning method, the LOQ must be at least 10% of the 
residue limit for the swab sample, so that robustness of the cleaning process can be 
established [4,6,7,29-31]. 
1.3.5.1.4. Precision (method and swabs) 
The precision of an cleaning analytical method is the closeness of agreement 
between the results obtained from multiple sampling by applying the analytical method 
and the sampling methodology under prescribed conditions that may include 
repeatability, intermediate precision and reproducibility [4,6,7,29-31]. 
1.3.5.1.5. Accuracy  
The accuracy of a cleaning method measures the closeness to the true value. It 
is measured by recovering the residue from various product contact surfaces such as 
stainless steel and silicone. The residue is recovered and analysed using the developed 
sampling methodology and analytical method [4,6,7,29-31]. 
1.3.5.1.6. Robustness 
Robustness is not a validation requirement, however it should be considered 
during the development of the analytical method. The robustness of an analytical 
cleaning procedure is a measure of its capability to remain unaffected by small 
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deliberate variations in methods parameters and provides an indication of its reliability 
during normal usage. The method parameters that may be altered include column 
temperature, flow rate, buffer and organic composition of the mobile phase         
[4,6,7,29-31]. 
1.3.5.1.7. Swab sample stability 
Swab sample stability is not a validation requirement but the stability of the 
swab samples may be evaluated if there if a significant interval between the swab 
sampling and the analysis of the swab samples. The swab sample study is conducted 
under the normal storage conditions, i.e. vial for storage, time and temperature [6,7].  
1.4. Sampling methodologies 
1.4.1. Introduction 
The two most common types of sampling techniques are swabbing and rinsing. 
These techniques have been addressed by the FDA, and are identified in many 
publications [1,3-7]. In the 1993 FDA cleaning validation guide, the FDA states that; 
“the most desirable is the direct method of sampling the surface of the equipment”; 
swab sampling must therefore be the primary method of sampling in support of 
cleaning validation [1]. Swab sampling methodologies are a critical aspect in 
establishing a robust validated cleaning program. They are essential to accurately 
determine and quantitate API residues remaining on the manufacturing equipment 
trains. The results of the swab samples that are analysed using the validated analytical 
cleaning method are compared to the maximum allowable carryover (MAC) limits to 
determine the robustness and effectiveness of the cleaning program [3-7,32,33]. 
1.4.2. Swab sampling 
Swab sampling involves wiping a surface with a fibrous material saturated with 
solvent (e.g., water or alcohol) to dissolve residue on the manufacturing equipment. A 
dimensionally defined surface area and defined technique are required for swab 
sampling. Swab sampling is adaptable to a wide variety of surfaces (stainless steel, 
glass, silicone, etc.) and allows for both dissolution and physical removal of residues. 
Additionally, areas that are hard to clean and which are reasonably accessible can be 
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evaluated, leading to establishing a level of contamination or residue per given surface 
area (µg/cm
2
). Swab sampling is the sampling technique recommended by the FDA, 
and it must be supported by recovery studies in which the swabbing technique is 
demonstrated to remove an acceptable percentage (≥ 50%) of product residue from the 
manufacturing equipment surfaces [1,3-7]. 
1.4.3. Swab selection 
There is a direct physical interaction between the swab, the solvent, the surface, 
and the residue to be removed. Therefore, the choice of swab is crucial to the 
effectiveness of the sampling procedure. The swab material should have an appropriate 
level of sorptive properties. The material must be sorptive enough to pick up 
acceptable levels of residue from the surface, but cannot be so sorptive, that it may not 
release the analyte from the swab for acceptable recoveries. The selection of swab to 
be used requires an evaluation of the swab properties, such as interferences and 
shedding properties as the swabbing material may interfere with the analysis of the 
samples. For example, the adhesive used in swabs has been found to interfere with the 
analysis of samples [3-7]. 
Polyester swabs that are specially processed to meet the stringent requirements 
associated with cleaning validation protocols are often the best choice and are the most 
commonly swabs used for cleaning validation. An example of a TX761 polyester swab 
in shown below in Figure 1.4. Polyester swabs offer high absorbency of residues, ultra-
low particulates, and minimal extractable interferences. The specially processed 
polyester material in combination with the analytical cleaning method can provide 
desirable analytical characteristics that other materials such as cotton, nylon or 
polyurethane foam cannot meet [6,7,34]. 
 
Figure 1.4: A Tex-wipe TX761 polyester swab. 
 
Jenkins et al. [35] screened a number of materials for their suitability as 
swabbing materials for total organic carbon (TOC) analysis. Some of the materials 
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tested included 100% polyester, woven cotton, polyurethane foam, a nonwoven 
polyester/cellulose and quartz wool. The criteria for the materials tested were; minimal 
interferences from the swab, high recovery rates of the analyte from the selected 
surfaces and low particle generation from the swab. The 100% polyester materials 
were the only materials that met all the above criteria. Quartz wool met the criteria for 
minimal interferences and recovery rates, but its excessive particle generation was 
deemed unacceptable for surface sampling for TOC analysis. Several materials were 
tested for non-volatile residues and it can be seen from Figure 1.5 that the 100% 
polyester swabs feature extremely low non-volatile residues [34,35].   
 
Figure 1.5: The comparison of levels of non-volatile residues from 100% polyester swabs 
versus other commonly used swab materials reported by Jenkins et al. [7]. 
1.4.4. Swab sampling recovery studies 
Sampling recovery studies are laboratory studies involving product contacting 
materials (coupons) that are representative of the actual manufacturing equipment 
surfaces. The coupons may be constructed of stainless steel, glass, teflon (PTFE, 
Polytetrafluoroethylene), EPDM (ethylene propylene diene monomer) or silicone. 
Examples of product contacting coupons are shown below in Figure 1.6. A standard 
solution containing the API residue to be quantitated is applied onto the coupon. The 
coupon is swabbed with the defined swab and extraction solvent to extract the residue, 
and the residue is analysed by the chosen analytical technique [3-7]. These studies 
demonstrate that if a residue is present on the manufacturing equipment surfaces, it can 
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be quantitatively recovered by the analytical method in combination with the sampling 
procedure. The objective is to establish a reproducible and acceptable level of recovery 
from the equipment surfaces [1,3-7].  
 
 
Figure 1.6. Examples of product contacting surface coupons. 
Different product contacting materials have different recovery performances. 
Stainless steel surfaces differ in degree of polish or surface roughness. Polymeric 
surfaces such as EPDM may have different porosities. The same residue may be highly 
recovered (e.g., ≥ 90%) from stainless steel but poorly recovered (≤ 20%) from EPDM 
(ethylene propylene diene monomer), as further discussed in Chapter 3. The selection 
of swab material and solvent used for swabbing purposes are important factors, since 
they can have an impact on recovery and influence extractables or interferences. 
Recovery of residues from the equipment surfaces may also depend on the size and 
shape of the swab head, as well as the properties (such as flexibility and length) of the 
swab handle. Another factor which may affect the recoveries is the pressure of the 
swab head that is applied to the surface during sampling. It is important to apply 
enough pressure to make the swab head flat, but not so much that movement cannot be 
controlled, as shown in Figure 1.7 [6,7,32,34]. The steps for performing swab recovery 
studies are outlined in Section 1.4.4.1. 
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Figure 1.7: Pressure effects of the swab head against the surface. 
1.4.4.1. Swab recovery studies, see Figure 1.8. 
 A known amount of a standard solution containing the drug substance residue   
is applied (spiked) onto a defined area of product contacting material. The 
product contacting material should be equivalent to the actual manufacturing 
equipment materials to be swabbed in cleaning validation. 
 
 The defined area is carefully swabbed using the defined solvent and technique  
       to transfer the residue from the product contacting material to the swab. 
 
 The swab is extracted with solvent to transfer the drug substance residue from  
       the swab for quantitative analysis. 
 
 The percent recovery of the drug substance residue from the product contacting  
       material is calculated as below;  
 
% Recovered =         Actual amount recovered by swabbing x 100% 
             Theoretical amount spiked onto the surface 
 
 
Figure 1.8: Recovery schematic for swab sampling. 
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1.4.4.2. Correction Factor 
A recovery of ≥ 50% from the swab sampling accuracy studies is acceptable if 
the results are reproducible and a correction factor is applied to the cleaning process. A 
correction factor is generally applied to the results obtained from the swab sampling 
studies. This correction factor is used to calculate the ‘true’ amount of residue that 
remains on the manufacturing equipment surfaces after the cleaning process has taken 
place. An example calculation is shown below [3-7]. 
 
𝑀 =
𝑀𝑟𝑒𝑠
𝐶
 
Where,  
 
  
M =   True value for the amount of residue remaining on the manufacturing 
equipment after cleaning 
Mres =   The measured amount of residue on the manufacturing equipment 
surface, µg/cm
2 
C =   Correction factor, e.g. for 75%, 75/100 = 0.75 
 
1.4.5. Swab sampling procedure 
  The swab used for the sampling procedure is typically pre-wetted with water or 
another appropriate solvent. This removes the drug substance residues from the 
product contacting surface. The sides of the swab are pressed against the inside of the 
sampling vial after pre-wetting prior to sampling to remove the excess solvent. It is 
important to remove the excess solvent as this can serve as a source of residues leading 
to variable results. Excess solvents may leave extractable substances of interest on the 
surface of the swab which can reduce the percent recovery or indicate a false positive 
result for a successful cleaning validation. Also, it is important to ensure that there is 
not a time delay between pre-wetting the swab and sampling the product-contact 
surface. A time delay may cause the solvent to evaporate. Therefore, there would be 
insufficient alcohol on the swab to recover the residue which would potentially cause a 
false negative result [3-7]. 
The product contacting surface is sampled with the defined swabbing 
procedure. The swabs are placed in the sample vial with the extraction solvent. The 
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extraction solvent releases the drug substance residue from the swab. The swab sample 
may need to be filtered or sonicated depending on the sample type. These steps may 
impact the analytical results if leaching occurs from the various materials involved. 
Therefore, the use of the highest quality suitably engineered swabs can provide 
assurance that any extraneous contamination observed in the analytical analysis does 
not originate from the swab. In addition, blank extractions of the swab and blank 
extractions of the product contacting surfaces used for the swab sampling studies are 
run to investigate for interferences in the chromatographic analysis of the sample        
[3-7, 31].  
 
1.5. Thesis Objectives 
In pharmaceutical industries, it is crucial to prove that the manufacturing 
equipment is consistently cleaned from API residues, to prevent possible 
contamination and cross-contamination of product batched. Therefore, cleaning 
validation is carried out. The analytical methods used to the detect trace residues are an 
important aspect of a cleaning validation. With ever increasing regulatory 
requirements, it is crucial to employ specific, sensitive analytical methods that are 
capable of quantitating trace level residues, while still retaining the repeatability and 
robustness necessary for QC laboratories. Swab sampling studies are required to 
demonstrate that a residue, if present on equipment surfaces, can be adequately 
quantitated by the analytical cleaning method in combination with the swab sampling 
procedure. The analytical cleaning method used in combination with the swab 
sampling procedure should be challenged to show that sufficient amounts of API 
residues can be effectively removed from the product contacting manufacturing 
equipment surfaces. An effective swab sampling procedure is an integral, if not 
dominating part of the cleaning validation method. UPLC is a powerful analytical 
technique that is widely used for the determination and quantitation of API residues in 
support of cleaning validation. It advantages over HPLC include shorter analysis 
times, a decrease in solvent consumption and greater sensitivity. 
The aim of this thesis was to develop and validate a specific, sensitive and 
robust UPLC analytical cleaning method for the simultaneous determination and 
quantitation of a range of API residues found in ophthalmic solutions. The 
development of the UPLC method involves the use of columns packed with sub-2 µm 
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particles for increased sensitivity, speed and better resolution. A Design of 
Experiments (DOE) approach utilising Dry Lab and Minitab software was adopted to 
facilitate rapid method development and ensure the desired resolution (≥ 2.0) between 
each peak pair. In addition, the related swab sampling was also developed and 
validated using various swabs, solvents and product contacting surfaces.  
In Chapter 2, the aim was to develop a relatively fast and robust UPLC 
analytical cleaning method to enable the simultaneous determination and quantitation 
of up to 10 different API residues that are found in various ophthalmic solutions. The 
APIs used for this research included brimonidine tartrate, timolol maleate, ketorolac 
tromethamine, flurbiprofen, prednisolone acetate, prednisolone, dexamethasone, 
fluorometholone and ofloxacin. These drug substances are in a wide range of 
ophthalmic solutions, and some of the ophthalmic solutions may contain the listed 
drug substances in different combinations. Hence, the analytical method was designed 
to have a broad applicability. 
 Chapter 3 details the swab sampling methodology that was carried out in 
combination with the developed UPLC method to show that the selected API residues 
can be sufficiently removed from the manufacturing equipment surfaces. A DOE 
approach was used to choose the most appropriate swab and solvent for adequately 
removing the residues from the surfaces. An important aspect was to investigate any 
interferences originating from the swab and the product contacting surfaces. 
 Chapter 4 summarizes the results obtained in this work and details any 
potential for future work.   
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Chapter 2 
 
Development of an Analytical Method for the Determination 
of API Residues in Support of Cleaning Validation by  
Ultra Performance Liquid Chromatography 
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2.1. Introduction 
The aim of the developed analytical method described in this Chapter was to 
quantitate the residues of a range of drug substances that included brimonidine tartrate, 
timolol maleate, ketorolac tromethamine, flurbiprofen, prednisolone acetate, 
prednisolone, dexamethasone, fluorometholone and ofloxacin in support of cleaning 
validation. These drug substances are in a wide range of ophthalmic solutions, and 
some of the ophthalmic solutions may contain the listed drug substances in different 
combinations. Hence, the analytical method was designed to have a broad 
applicability. 
Depending on the class of drug substance, some of these compounds may be 
grouped together for analysis. For example, the corticosteroids; prednisolone acetate, 
prednisolone, dexamethasone, and fluorometholone have been determined using 
isocratic or gradient conditions in different combinations [1-4]. The simultaneous 
detection of the β-adrenergic receptor blockers, timolol maleate and levobunolol 
hydrochloride has also been reported [5-6] along with several analysis in the literature 
of them being quantitated separately [7-9]. There are many analytical methods 
described for the simultaneous quantitation of fluoroquinolones, one of which is 
ofloxacin [10-12]. There are also analysis methods described for the detection of 
brimonidine tartrate [13-15], flurbiprofen [16-18] and ketorolac tromethamine [19-21] 
quantitated with compounds of the same drug class. 
Gradient elution is often used for the separation of analytes in a sample with a 
wide range of molecular weights and/or polarities. For these types of samples, 
gradients are useful to screen for appropriate conditions and provide an adequate 
separation within a reasonable run time [22]. There are numerous gradient analysis 
analytical methods described in the literature for the separation and determination of 
brimonidine tartrate, timolol maleate, levobunolol hydrochloride, ketorolac 
tromethamine, flurbiprofen, prednisolone acetate, prednisolone, dexamethasone, 
fluorometholone and ofloxacin, as mentioned previously. 
This Chapter describes a robust UPLC liquid chromatography analytical 
method for the separation and quantitation of up to 10 different drug substances, which 
will cover a broad range of ophthalmic solutions. The separation is for a mixture of 
acidic, basic and neutral drug substances which is not typical of most pharmaceutical 
applications as it consists of drug substances with significantly different pKa, Log P 
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and Log D values. A Design of Experiments (DOE) approach utilising Dry Lab and 
Minitab software was adopted to facilitate rapid method development and ensure the 
desired resolution (≥ 2.0) between each peak pair. 
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2.2. Experimental 
2.2.1. Reagents and materials 
Reference materials, dexamethasone (DEX, 99.7%), prednisolone acetate 
(PAC, 99.4%), and fluorometholone (FML, 99.7%) were purchased from Sanofi 
Aventis (Paris, France),  levobunolol hydrochloride (BUN, 99.7%) and brimonidine 
tartrate (BMT, 99.9%) from Piramal Healthcare (Andhra Pradesh, India), timolol 
maleate (TIM, 99.9%) from PCAS Finland OY (Turka, Finland), ketorolac 
tromethamine (KET, 98.7%) from Recordati (Milan, Italy), ofloxacin (OFL, 99.7%) 
from Chemo (Madrid, Spain), prednisolone (POH, 98.5%) from Sigma Aldrich          
(St. Louis, Missouri, US), and flurbiprofen (FBP, 99.6%) from Aesica Pharmaceuticals 
Limited (Cramlington, UK). The structure, abbreviation, and pharmaceutical class of 
each of the drug substances in this mixture and their pKa, Log P and Log D values are 
shown in Table 2.1.  
Analytical grade ammonium acetate was purchased from Merck (Darmstadt, 
Germany) and ammonium hydroxide solution (34%) from Lennox (Cambridge, UK). 
Phosphoric acid (85%) and acetic acid were purchased from Sigma Aldrich (Arklow, 
Ireland). HPLC grade methanol (MeOH) and acetonitrile (ACN) were purchased from 
Labscan (Dublin, Ireland). All chemicals were used as received, without any further 
purification. Deionised water was obtained from a Millipore Milli-Q water purification 
unit (Millipore, Bedford, MA, USA).  
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Table 2.1: The chemical structure, abbreviation, pharmaceutical class, pKa value,     
Log P, and Log D values of each drug substance. 
Structure
1
 Pharmacologic 
class 
pKa values Log P Log D 
Dexamethasone (DEX) 
 
 
Synthetic 
Corticosteroid 
 
 
12.42 [23] 
 
 
1.83 [24] 
 
 
1.83 [24] 
 
Fluorometholone (FML) 
 
 
Synthetic 
Corticosteroid 
 
 
12.64 [23] 
 
 
2.00 [24] 
 
 
2.00 [24] 
Prednisolone (POH) 
 
 
Synthetic 
Corticosteroid 
 
 
12.58 [23] 
 
 
1.62 [24] 
 
 
1.62 [24] 
 
Prednisolone acetate (PAC) 
 
 
Synthetic 
Corticosteroid 
 
 
12.61 [23] 
 
 
2.40 [24] 
 
 
2.40 [24] 
 
Ketorolac tromethamine (KET) 
 
Non-steroidal 
anti-
inflammatory 
drug 
 
8.95[23] 
 
 
 
 
 
 
3.84 [23] 
-7.8 [23] 
 
 
 
 
 
 
 
 
 
2.28 [23] 
 
 
 
 
 
 
 
 
0.84 (pH 5.5) [25] 
-0.95 (pH 7.4) [25] 
 
 
                                                          
1 
These are the counter ions of the drug substances, i.e tromethamine, hydrochloride, tartrate, and 
maleate.  
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Table 2.1 (continued) 
Structure
1
 Pharmacologic 
class 
pKa values Log P Log D 
 
 
Flurbiprofen (FBP) 
 
 
Non-steroidal 
anti-
inflammatory 
ophthalmic 
 
 
4.42 [23] 
 
 
4.16 [24] 
 
 
2.74 (pH 5.5) [25] 
0.98 (pH 7.4) [25] 
Ofloxacin (OFL) 
 
 
Fluoroquinolone 
 
 
5.45 [23] 
6.2 [23] 
 
 
-0.39 [24] 
 
 
-1.17 (pH 5.5) [25] 
-1.41 (pH 7.4) [25] 
 
Timolol maleate (TIM) 
 
 
Beta-adrenergic 
blocking agent 
 
 
 
9.76 [23] 
14.08 [23] 
-0.32 [23] 
 
 
 
 
 
 
 
5.91 [26] 
3.05 [26] 
 
 
1.83 [27] 
 
 
-2.34 (pH 5.5) [28] 
-1.20 (pH 7.4) [28] 
 
Levobunolol hydrochloride 
(BUN) 
 
 
Beta-adrenergic 
blocking agent 
 
 
 
9.66 [26] 
 
 
2.40 [27] 
 
 
0.84 (pH 5.5) [28] 
-0.95 (pH 7.4) [28] 
      
Brimonidine tartrate (BMT) 
 
 
Alpha-
adrenergic 
receptor agonist 
 
 
 
8.32 [26] 
 
 
 
 
 
 
4.49 [26] 
2.72 [26] 
13.03 [26] 
14.44 [26] 
 
 
1.37 [26] 
 
 
0.84 (pH 5.5) [28] 
-0.95 (pH 7.4) [28] 
 
 HCL 
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2.2.2. Instrumentation 
The chromatographic separation was performed using a Waters Acquity           
H-Class Ultra Performance Liquid Chromatography (UPLC) system, which comprised 
of a vacuum degasser, a quaternary solvent manager, a sample manager, an auto 
sampler with temperature control, a column pre-heater and a photodiode array (PDA) 
detector with ultraviolet (UV) channels. The columns chosen were a Waters Acquity 
High Strength Silica (HSS) C18 (1.8 µm, 2.1 mm x 100 mm) column (Waters, Santry, 
Dublin, Ireland) (Column A) and a Waters Acquity Charged Surface Hybrid (CSH) 
C18 (1.7 µm, 2.1 mm x 100 mm) column (Waters, Santry, Dublin, Ireland) (Column 
B). Features of Column A and Column B are shown below in Table 2.2. 
          Table 2.2: Features of Column A and Column B. 
Features Column A (HSS) Column B (CSH) 
Endcapping √ √ 
Ligand density 3.2 µmol/m
2
 2.3 µmol/m
2
 
Carbon load 15% 15% 
Surface area 230 m
2
 185 m
2
 
Pore Size 100 Å 135 Å 
 
A Branson sonication bath model 8510 (Branson Ultrasonics Corporation, 
Danbury, USA) was used for dissolving the standard reference materials and the 
balance used was a Mettler Toledo model XS205 (Manson Technology, Dublin, 
Ireland). The pH meter used (Orion 3 Star) was purchased from Thermo Electron 
Corporation (Thermo, PA, USA).  
Mobile phase pH, gradient times and solvent strength optimisation was 
performed using Dry Lab 2000 Plus Chromatography optimisation software (Molnar-
Institute Berlin, Germany) and Minitab software was used to predict optimal mobile 
phase pH and buffer concentration of the mobile phase. 
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2.2.3. Method 
The chromatographic analysis on Column A was performed using 50 mmol L
-1 
sodium phosphate buffer (pH 2.5 or 6.0, adjusted with phosphoric acid) or                  
50 mmol L
-1 
sodium acetate buffer (pH 4.6, adjusted with acetic acid) as mobile phase 
A and ACN as mobile phase B. The gradient programme used was a linear gradient 
from 0-20 minutes (15-85% B). 
 The chromatographic analysis on Column B was performed using 40 mmol L
-1 
ammonium acetate buffer (pH 9.85, adjusted with ammonium hydroxide solution) as 
mobile phase A and 40 mmol L
-1 
ammonium acetate buffer (pH 9.85)/ACN (50/50, 
v/v) as mobile phase B. The gradient programme was a linear gradient from 0-10 
minutes (30-100% B). 
 Both Column A and Column B had a 3 minute column re-equilibration time
2
. 
The flow was set at 0.4 mL min
-1 
and the column temperature was maintained at 30 °C 
for both columns. Additionally, the injection volume was 5 µL, with detection by UV 
at 254 nm for BMT, FBP, PAC, POH, BUN, DEX and FML, and 295 nm for OFL, 
KET and TIM for both Column A and Column B. 
2.2.4. Standard preparation 
Stock standard solutions of BMT, KET, FBP, TIM, and BUN were prepared in 
deionised water; PAC, POH, OFL and DEX in MeOH:water (70:30, v/v); and FML in 
methanol, each at a concentration of 500 µg/mL. The standards were stored in a 
refrigerator at 4 °C, for two weeks with no significant loss of API. Working standards     
(5 µg/mL) were prepared fresh from the stock solutions before analysis in ACN:water 
(5:95, v/v).  
 
 
 
 
 
                                                          
2
 3 minute column equilibration time; The column was washed for 3 minutes at the end of each 
chromatographic run with the same mobile phase composition as the start of the gradient. This step was 
employed to re-equilibrate the column back to the original conditions before each injection.  
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2.3. Results and discussion 
2.3.1. Optimisation of chromatographic conditions 
Two different columns were used in optimizing chromatographic conditions;   
Column A and Column B. Column A, a general-purpose silica-based C18 column, was 
primarily used to scout for conditions. Mobile phase pH was investigated in optimizing 
the chromatographic conditions for Column A, and mobile phase pH, buffer 
concentration, column temperature, and gradient optimisation were investigated for 
Column B. The desired criteria for an optimal separation were a resolution of ≥ 2.0 
between every peak pair and tailing of ≤ 2.0 for every drug substance.  
2.3.1.1. Optimisation of mobile phase pH on Column A 
One of the most widely used columns is an octadecyl carbon chain (C18)-
bonded silica (USP classification L1) which was the column type chosen for this 
separation. Initially, the separation was developed using Column A which is a general-
purpose silica-based C18 column with applicability to a broad range of drug substance 
classes (as stated by the manufacturer). Another advantage of the high strength silica-
based material is that it can withstand high UPLC pressures (15,000 psi), and has a 
mobile phase pH range of between 1 and 8 (manufacturers recommendation).  
The impact of mobile phase pH on the retention of brimonidine tartrate, timolol 
maleate, ketorolac tromethamine, flurbiprofen, prednisolone acetate, prednisolone, 
dexamethasone, fluorometholone and ofloxacin were investigated on Column A and 
the results are presented below. For these experiments, a scouting gradient of 15-85% 
B over 20 minutes was employed to ensure elution of all drug substances.  
2.3.1.1.1. Impact of pH on retention 
The effect of mobile phase pH on the retention of the ten drug substances was 
studied in the range of 2.5 to 6.0, as shown in Figure 2.1. The drug substances fall into 
different groups. For one group (POH, DEX, PAC, and FML), the retention was 
unaffected by pH which is consistent with their lack of ionisable groups. It is also 
interesting to note that at all three pH values (pH 2.5, 4.6 and 6.0), the BMT peak 
exhibited very poor retention. The basic functional groups of BMT were ionised in this 
acidic pH range which contributed to its lack of retention on a nonpolar stationary 
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phase as shown in Table 2.3. Even though the pH range was relatively narrow, the 
influence of the mobile phase pH on the retention of KET and FBP was significant. As 
can be seen in Table 2.3, an increase in mobile phase pH led to a decrease in retention 
of FBP and KET, as they became more ionised and less retained.  
 
Figure 2.1: The effect of mobile phase pH on the separation of the 10 drug substances at (a) 
pH 2.5, (b) pH 4.6, and (c) pH 6.0. Column A. Mobile phase A: 50 mmol L
-1
 sodium phosphate 
buffer (pH 2.5), mobile phase B: 100% ACN. Gradient program: 0-20 minutes (15-85% B). 
Flow rate: 0.4 mL min
-1
. Column temperature: 30 °C. Injection volume: 5 µL. Detection: 254 
nm. Peaks: (1) BMT, (2) OFL, (3) TIM, (4) BUN, (5) POH, (6) DEX, (7) KET, (8) PAC, (9) 
FML, and (10) FBP. 
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 Table 2.3: The effect of acidic mobile phase pH on the retention of BMT, FBP and 
 KET.  
Drug 
Substance 
pKa Value Retention 
Time (mins)  
pH 2.5 
Retention 
Time (mins)  
pH 4.6 
Retention 
Time (mins)  
pH 6.0 
BMT 8.32 [26] 0.4 0.4 0.4 
FBP 4.42 [26] 10.2 9.1 5.8 
KET 3.84 [26] 6.5 4.2 2.5 
 
2.3.1.1.2. Impact of pH on resolution  
At pH 2.5 and 4.6, the KET peak was significantly resolved from all other drug 
substances, but at pH 6.0 the KET peak did not achieve baseline resolution3 from the 
BUN as shown is Table 2.4. All other peak pairs met the resolution criterion of ≥ 2.0 
for all the pH variances. The resolution data between adjacent pairs for all the drug 
substances in the chromatographic run at pH 2.5, 4.6 and 6.0 are shown below in        
Table 2.4. 
   Table 2.4: The effect of acidic mobile phase pH on the resolution between adjacent    
   peak pairs. 
Drug Substance/Peak number RS pH 2.5 RS pH 4.6 RS pH 6.0 
BMT (1)/OFL (2) 6.8 8.3 14.4 
OFL (2)/TIM (3) 6.9 7.9 8.9 
TIM (3)/BUN (4) 6.6 5.6 6.6 
BUN (4)/POH (5) 31.2 N/A N/A 
POH (5)/DEX (6) 21.5 21.4 N/A 
DEX (6)/KET (7) 3.3 N/A N/A 
KET (7)/PAC (8) 8.4 N/A N/A 
PAC (8)/FML (9) 3.3 3.4 3.2 
FML (9)/FBP (10) 33.2 21.7 N/A 
BUN (4)/KET (7) N/A 20.0 1.1 
KET (7)/ POH (5) N/A 10.0 34.6 
POH (5)/FBP (10) N/A N/A 15.1 
DEX (6)/PAC (8) N/A 12.5 13.1 
 
 
                                                          
3
 Resolution (RS): The resolution is the separation of two components in a mixture, calculated by: 
        RS = 1.18(tR2 –tR1)/(W1,h/2 + W2/h/2) 
Where, tR2 and tR1 are the retention times of the two components; and W2 and W1 are the corresponding 
widths at the bases of the peaks obtained by extrapolating the relatively straight sides of the peaks to the 
baseline. 
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2.3.1.1.3. Impact of pH on peak shape 
At pH 2.5, 4.6 and 6.0, the tailing4 of OFL was 0.91, 1.21 and 1.26, 
respectively, which meets the desired criterion of ≤ 2.0 for tailing, however a tailing 
value of 0.91 for pH 2.5 indicates fronting of the OFL peak. Additionally, the OFL 
peak shape is not acceptable at pH 2.5 and 4.6 as shown from the inserts in Figure 2.1.  
2.3.1.2. Optimisation of mobile phase pH on Column B 
The issues with Column A were (a) poor retention of BMT, (b) poor peak shape 
for OFL and (c) poor resolution of BUN/KET. It is interesting to note that BMT, BUN 
and OFL are basic drug substances under these experimental conditions. Hence,      
Column B was investigated as an alternative stationary phase relative to Column A. 
The best overall separation on Column A was achieved at pH 6.0, with respect to the 
shape of the OFL peak, as shown in Figure 2.1 (c). Column B is also a silica based C18 
column and it’s features include; 
 a charged surface hybrid particle platform 
 a controlled low-level surface charge to provide enhanced selectivity and peak 
shape for basic compounds (BMT, BUN, TIM, OFL) at low and high pH 
 an expanded mobile phase pH of 1-11  
 
Surface charges have a major impact on the behaviour of ionized analytes. 
According to the vendor, a new surface modification process was developed that 
allows the introduction of a reproducible, low level positive charge in acidic 
mobile phases. In basic mobile phases, ionization of silanol groups creates a 
negative charge [29]. The CSH technology process is shown in Figure 2.2.  
 
 
                                                          
4
 Symmetry factor (AS)
2
: The symmetry factor (also known as the tailing factor) is calculated by: 
        AS = W0.05/2f 
Where, W0.05 is the width of the peak at 5% height and f  is the distance from the peak maximum to the 
leading edge of the peak, the distance being measured at a point 5% of the peak height from the 
baseline. 
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      Figure 2.2: CSH Technology Process. 
 
If low mobile phase pH conditions do not aid in the retention of a basic 
compound (BMT) as shown in Figure 2.1, then a mobile phase with a pH of greater 
than 8 must generally be used to supress the charge on the basic compound [30]. 
Firstly, Column B was compared to Column A using the optimal conditions achieved 
using Column A, which were shown to be a mobile phase of pH 6.0 (Figure 2.1(c)). 
The comparison of Column A versus Column B is shown in Figure 2.3. 
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Figure 2.3: A comparison of Column A (a) versus Column B (b) using mobile phase pH 6.0 on 
the separation of the 10 drug substances. Column A/Column B. Mobile phase A: 50 mmol L
-1 
sodium phosphate buffer (pH 6.0), mobile phase B: 100% ACN. Gradient program: 0-20 
minutes (15-85% B). Flow rate: 0.4 mL min
-1
. Column temperature: 30 °C. Injection volume: 
5 µL. Detection: 254 nm. Peaks: (1) BMT, (2) OFL, (3) TIM, (4) BUN, (5) POH, (6) DEX, (7) 
KET, (8) PAC, (9) FML, and (10) FBP. 
 
2.3.1.2.1. Impact of pH on retention  
As shown from Figure 2.1, BMT exhibited poor retention with pH 6.0 mobile 
phase using Column A. The retention of BMT improved using Column B, however 
BMT/OFL were now shown to be co-eluted (Figure 2.3 (b)). In order to suppress the 
charge on BMT which is a basic drug substance, a high pH range was investigated in 
the approximate range for ammonia buffers of between pH 8.7 to 10.0 using ACN as 
mobile phase B as shown in Figure 2.4.  
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Figure 2.4: The effect of mobile phase pH on the separation of the 10 drug substances at            
(a) pH 8.7, (b) pH 9.2, and (c) pH 10.0. Column B.  Mobile phase A: 25 mmol L
-1
 ammonium 
acetate buffer, mobile phase B: 100% ACN. Gradient program: 0-20 minutes (15-85% B). 
Flow rate: 0.4 mL min
-1
. Column temperature: 30 °C. Injection volume: 5 µL. Detection: 254 
nm. Peaks: (1) BMT, (2) OFL, (3) KET, (4) TIM, (5) BUN, (6) FBP, (7) POH, (8) DEX, (9) 
PAC, and (10) FML.  
 
2.3.1.2.2  Impact of pH 8.7, 9.2 and 10.0 on retention  
 At the three high pH values (pH 8.7, 9.2 and 10.0), the BMT peak exhibited 
better retention relative to the more acidic pH range (Figure 2.1). The change in 
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selectivity of OFL and BMT using the higher pH range is evident from Table 2.5. The 
elution order of BMT/OFL reverses from pH 8.7 to pH 10.0.  
2.3.1.2.3. Impact of pH on tailing and resolution 
Even though the range was narrow, the influence of pH on the resolution 
between some of the drug substance peak pairs was significant. For instance, there is a 
significant difference in the tailing of OFL at the high pH range as shown in below in 
Table 2.5. At pH 8.7, the tailing of OFL is 3.6, and at pH 9.2 BMT/OFL are co-eluting. 
Additionally to BMT/OFL co-eluting at pH 9.2, this pH range also caused co-elution 
between TIM/FBP and POH/BUN. At pH 8.7 and 10.0, the resolution between all drug 
substance peak pairs was ≥ 2.0, except for BUN at pH 10.0 (RS: 1.5).  
Table 2.5: The effect of basic mobile phase pH on the retention/tailing of OFL and 
BMT.  
Parameter pH 8.7 pH 9.2 pH 10.0 
Retention Time OFL 2.0 1.7 1.4 
Retention Time BMT 1.6 1.7 1.7 
Tailing OFL 3.6 BMT/OFL are 
co-eluting 
1.2 
 
Of all the high pH mobile phases, the best separation was achieved using a 
mobile phase of pH 10.0. The resolution between all drug substances was ≥ 2.0, except 
for BUN/DEX (RS: 1.5), and the tailing of all ten drug substances was ≤ 2.0. 
BUN/DEX achieved baseline resolution of 1.5, but did not achieve the desired 
resolution of ≥ 2.0. This drug substance peak pair was therefore the focus of further 
method optimisation, as described hereafter/in Section 2.3.1.4. Additionally, resolution 
was not achieved between the impurities of PAC with FML and DEX as described 
below in Section 2.3.1.2.4. 
2.3.1.2.4. Impact of pH on resolution of PAC and it’s impurities 
Prednisolone acetate contains the impurities, prednisolone 17-acetate (P17-AC) 
and hydrocortisone acetate (HAC), in addition to POH as shown in Figure 2.5. 
Baseline resolution (≥ 1.5) was achieved between all ten drug substances at pH 10.0. 
However, at this pH, there was co-elution between DEX/P17-AC and FML/HAC, as 
shown in Figure 2.6. The impurities of PAC, P17-AC and HAC are structurally very 
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similar to DEX and FML (Figure 2.7), which makes the separation particularly 
challenging. An overlay of a PAC standard containing POH, P17-AC and HAC, and a 
standard containing all ten drug substances at pH 10.0 is shown in Figure 2.6. 
 
Figure 2.5: The effect of mobile phase pH on the separation of PAC and impurities at pH 10.0 
Column B.  Mobile phase A: 25 mmol L
-1
 ammonium acetate buffer, mobile phase B: 100%.  
Gradient program: 0-20 minutes (15-85% B). Flow rate: 0.4 mL min
-1
. Column temperature:       
30 °C. Injection volume: 5 µL. Detection: 254 nm. Peaks: (1) POH, (2) P17-AC, (3) PAC, (4) 
HAC. Note: Chromatogram is zoomed in from 5.5 to 9 minutes to show clearly the PAC and 
it’s impurities. 
 
Figure 2.6: The effect of mobile phase pH 10.0 on the separation of PAC and impurities 
overlaid with a standard containing the ten drug substances. Column B. Mobile phase A: 25 
mmol L
-1 
ammonium acetate buffer, mobile phase B: 100% ACN. Gradient program: 0-20 
minutes (15-85% B). Flow rate: 0.4 mL min
-1
. Column temperature: 30 °C. Injection volume: 
5 µL. Detection: 254 nm. Peaks: (1 ) POH, (2) TIM, (3) BUN, (4) DEX, (5) P17-AC, (6) 
system peak, (7) PAC, (8) FML, and (9) HAC. Note: Chromatogram is zoomed in from 5.5 to 
9 minutes to show clearly the co-elution of the PAC impurities with DEX and FML. 
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Figure 2.7: Structures of (a) prednisolone 17-acetate, (b) hydrocortisone acetate,                         
(c) dexamethasone and (d) fluorometholone. 
2.3.1.3. Separation of the critical peak pairs (DEX/P17-AC, FML/HAC) using Dry Lab 
Software on Column B 
 
Results from the initial screening experiments detailed above indicated that a 
pH in the region of 10.0 with a linear gradient of 0-20 minutes (15-85% B) provided 
good retention, resolution and tailing for the ten drug substances as shown in Figure 
2.4 (c). However, as shown in Figure 2.6 there was co-elution between DEX/P17-AC 
and FML/HAC due to their similarities in chemical structures. In an effort to achieve 
baseline resolution between the two critical pairs, DEX/P17-AC and FML/HAC, Dry 
Lab software was utilised. DEX, FML, P17-AC and HAC are all neutral drug 
substances. The retention of neutral drug substances are generally not affected by 
buffer concentration or mobile phase pH in reverse phase chromatography, therefore 
column temperature and gradient times were investigated as a means to separate the 
two critical pairs DEX/P17-AC and FML/HAC. 
 A design of experiments (DOE) utilising two gradients at two column 
temperature chromatographic runs were carried out using the ten drug substances to 
provide data input for the Dry Lab software to predict the optimal column temperature 
and gradient conditions which would give resolution (RS ≥ 2.0) between the critical 
pairs. These four chromatographic runs were chosen based on the following 
considerations:  
 
 
(a) (b) 
(c) (d) 
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(a) Gradient times should differ by a factor of 3 to 4 for Dry Lab predictions,  
(b) Column temperature should differ by at least 15 °C to 20 °C, 
(c) A wide gradient range of 15-85% B was chosen for all four chromatographic runs    
     so a broad design space could be modelled by Dry Lab.  
The model chromatographic runs are shown in Table 2.6. A 25 mmol L
-1
 ammonium 
acetate buffer (pH 10.0) as mobile phase A was employed. 
         Table 2.6: LC-RP Gradient/Temperature mode run parameters. 
Run 1 2 3 4 
tG 20 60 20 60 
Column Temp. (°C) 30 30 60 60 
  
The data from the DOE was imported into Dry Lab using the LC-RP 
Gradient/temperature (4 runs) mode and the Dry Lab resolution map and 
chromatogram generated as shown in Figure 2.8 and Figure 2.9. This map represents a 
plot of predicted resolution for DEX/P17-AC as a function of gradient time (tG) and 
column temperature. The two critical pairs are DEX/P17-AC and FML/HAC, but Dry 
Lab predicted DEX/P17-AC as the pair with the lowest peak resolution as shown from 
Figures 2.8 and 2.9, therefore DEX/P17-AC was the peak pair selected for further 
optimisation using Dry Lab. 
 
 
Figure 2.8: Dry Lab resolution map for the separation of DEX/P17-AC using the LC-RP 
Gradient/temperature mode to predict the highest peak resolution.  
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Figure 2.9: Dry Lab prediction for the separation of DEX/P17-AC using the LC-RP  
Gradient/temperature mode to predict the highest peak resolution. Column B. Mobile phase A:          
25 mmol L
-1
 ammonium acetate buffer, mobile phase B: 100% ACN. Gradient program: 0-48 
minutes (15-85% B). Flow rate: 0.4 mL min
-1
. Injection volume: 5 µL. Column temperature: 
60 °C. Detection: 254 nm. Peaks: (1) OFL, (2) BMT, (3) KET, (4) FBP, (5) POH, (6) TIM, (7) 
BUN, (8, 9) DEX, P17-AC (10) PAC (11,12) FML, HAC. 
 
Calculated peak resolutions of 0.0 to 1.94, in increments of approximately 0.24 
are shown as colour coded regions and give a visual representation of the robustness of 
the separation. A column temperature of approximately 60 °C and a tG of 48 shows the 
highest peak resolution for the separation of DEX/P17-AC, (RS: 1.94, predicted by Dry 
Lab). Separation of FML/HAC was also achieved at these conditions (RS: 2.00, 
predicted by Dry Lab). To verify the Dry Lab prediction, an experiment was carried 
out with a column temperature of 60 °C and a tG of 48 minutes. The chromatogram 
was zoomed in from 0-18 minutes to show the separation of DEX/P17-AC and 
FML/HAC (Figure 2.10). The predicted Dry Lab chromatogram shows that DEX/P17-
AC has the lowest peak resolution (RS: 1.94), however the experimental run shows 
DEX/P17-AC to be co-eluted. These results are contradictory, however Dry Lab was 
only used as an investigatory tool for the separation. 
Separation of DEX/P17-AC was not achieved under the experimental 
conditions (Figure 2.10) as predicted by Dry Lab. Further, a tG of 48 minutes is not an 
efficient run time for a cleaning validation method. In addition to this, a column 
temperature of 60 °C is generally not suitable for a CSH column, as the manufacturer’s 
recommendation for this column when using a high pH mobile phase is a maximum 
column temperature of 45 ºC. For these reasons, the PAC standard (containing 
impurities, P17-AC and HAC) was injected separately in future injections. In addition, 
44 
 
PAC contains POH, so for quantitation purposes, the PAC was ran on a separate 
injection. The remaining nine drug substances (OFL, BMT, KET, FBP, POH, TIM, 
BUN, DEX, and FML) were selected for further optimisation using Dry Lab. 
 
 
Figure 2.10: The effect of column temperature and gradient time on the separation of 
DEX/P17-AC and FML/HAC. Column B. Mobile phase A: 25 mmol L
-1 
ammonium acetate 
buffer (pH 10.0), mobile phase B: 100% ACN. Gradient program: 0-48 minutes (15-85% B). 
Flow rate: 0.4 mL  min
-1
. Column temperature: 60 °C. Injection volume: 5 µL. Detection: 254 
nm. Peaks: (1 ) OFL, (2) BMT, (3) KET, (4) FBP impurity, (5) FBP, (6) POH, (7) TIM, (8) 
BUN, (9) DEX, (10) P17-AC, (11) system peak, (12) PAC, (13) FML, and (14) HAC. Note: 
Chromatogram is zoomed in from 0 to 18 minutes to show clearly the separation of DEX/P17-
AC and FML/HAC 
 
2.3.1.4. Optimisation of the nine drug substances using Dry Lab Software  
Based on the results from Section 2.3.1.3, column temperature/gradient 
optimisation did not achieve separation of DEX/P17-AC, therefore PAC was removed 
from the standard mixture, leaving nine drug substances to optimise simultaneously. 
PAC was still included in the study, but was run as a separate injection and therefore 
co-elution between DEX/P17-AC and FML/HAC was no longer an issue. Dry Lab 
optimisation was therefore re-visited in light of removal of PAC and associated 
impurities (notably the impurity P17-AC) which heretofore had co-eluted with DEX. 
The nine remaining drug substances (OFL, BMT, KET, FBP, POH, TIM, BUN, DEX, 
FML) are a mixture of acidic, basic and neutral drug substances, so in order to achieve 
an optimal separation, mobile phase pH, gradient time and % organic of mobile phase 
B were investigated using Dry Lab. As shown previously in Section 2.3.1.2.3, BUN 
only achieved baseline resolution of 1.5 at mobile phase pH 10.0. 
45 
 
A DOE using LC-RP Gradient/pH (6 runs) runs were carried out and Dry Lab 
software was used to predict the optimal pH, organic content and gradient time, which 
would give resolution (RS ≥ 2.0) between the nine drug substances. As in the case of 
the previous Dry Lab experiment carried out (Section 2.3.1.3), column temperature and 
gradient times were chosen as the parameters in an effort to separate the two critical 
neutral pairs, DEX/P17-AC and FML/HAC. For optimal separation of the nine 
remaining drug substances, the six chromatographic runs were chosen based on the 
following considerations:  
(a) Gradient times should differ by a factor of 3 to 4 for Dry Lab predictions,  
(b) A pH range of 9.5 to 10.4, 
(1) A reasonable separation was achieved with Column B at approximately  
      pH 10.0                          
(2) The pH recommendation for Dry Lab is no more than 0.5 pH units 
(c) A wide gradient range of 15-85% B 
(d) A 25 mmol L
-1
 ammonium acetate buffer as mobile phase A and a column 
      temperature of 30 º C was employed. 
The DOE are summarized in Table 2.7. 
      Table 2.7: LC-RP Gradient/pH (6 runs) run parameters. 
Run 1 2 3 4 5 6 
tG 20 60 20 60 20 60 
pH 9.5 9.5 10.0 10.0 10.4 10.4 
 
The data from the DOE was imported into Dry Lab using the LC-RP 
Gradient/pH (6 runs) mode and the Dry Lab resolution map and chromatogram 
generated as shown in Figure 2.11 and Figure 2.12. This map shows that a pH range of 
between approximately 9.80 and 10.0 at a tG of 0-10 minutes 15-50% shows a peak 
resolution of approximately RS 2.5 to 4.4 for BUN/DEX. In Figure 2.12, there are now 
9 drug substances, instead of 10 as shown previously from the Dry Lab chromatogram 
in Figure 2.9. As discussed in Section 2.3.1.3, PAC was removed from the standard 
mixture due to PAC impurity co-elution issues and so as a consequence, BUN/DEX 
then became the critical drug substance peak pair (instead of DEX/P17-AC) as 
predicted by Dry LAB with the conditions described in Figure 2.12. 
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Figure 2.11: Dry Lab resolution map for the separation of BUN/DEX using the LC-RP 
Gradient/pH mode to predict the highest peak resolution. 
 
 
Figure 2.12: Dry Lab chromatogram for the separation of the nine drug substances using the 
LC-RP Gradient/pH mode to predict the highest peak resolution. Column B. Mobile phase A:            
25 mmol L
-1
 ammonium acetate buffer (pH  9.9) mobile phase B: 100% ACN. Gradient 
program: 0-10 minutes (15-50% B). Flow rate: 0.4 mL min
-1
. Injection volume: 5 µL. Column 
temperature: 30 °C. Detection: 254 nm. Peaks: (1) OFL, (2) BMT, (3) KET, (4) FBP, (5) POH, 
(6) TIM, (7) BUN, (8) DEX, (9) FML 
 
  
To verify the Dry Lab prediction, an experiment was carried out with a mobile 
phase of pH 9.9 and a tG of 10 minutes (15-50% B) as shown in Figure 2.13. The 
predictive ability of the Gradient/pH model was evaluated by comparing the predicted 
and experimentally obtained retention times as shown in Table 2.8. The compared 
retention times were in good agreement, with all the % retention time errors being         
≤ 10%. In the case of the resolutions obtained, the predicted Dry Lab chromatogram 
(Figure 2.12) shows that BUN/DEX has the lowest peak resolution (RS: 4.7), which is 
10 20 30 40 50 60tG
9.5
10.0
pH
0.00
0.62
1.25
1.87
2.49
3.11
3.74
4.36
4.98
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in agreement with the experimental run (Figure 2.13), which also shows BUN/DEX to 
have the lowest peak resolution (RS: 2.6). The results for resolution between 
BUN/DEX show some variability between the experimental and Dry Lab run, however 
Dry Lab was only used as an investigatory tool for the separation. 
 
Figure 2.13: The effect of mobile phase pH 9.9 on the separation of the 9 drug substances. 
Column B. Mobile phase A: 25 mmol L
-1
 ammonium acetate buffer, mobile phase B: 100% 
ACN. Gradient program: 0-10 minutes (15-50% B). Flow rate: 0.4 mL min
-1
. Column 
temperature: 30 °C. Injection volume: 5 µL. Detection: 254 nm. Peaks: (1) OFL, (2) BMT,     
(3) KET, (4) FBP, (5) POH, (6) TIM, (7) BUN, (8) DEX, and (9) FML.  
            Table 2.8: Dry Lab predicted and experimental retention times values.  
Peak 
name  
Predicted 
retention 
time 
(min) 
Experimental 
retention 
time  
(min) 
Difference 
between 
retention 
times (min) 
% error 
OFL 1.28 1.36 0.08 6.25 
BMT 1.57 1.69 0.12 7.64 
KET 2.66 2.64 0.02 0.75 
FBP 5.15 5.10 0.05 0.97 
POH 5.58 5.76 0.18 3.22 
TIM 6.07 6.42 0.35 5.76 
BUN 6.59 6.99 0.40 6.06 
DEX 7.00 7.17 0.17 2.42 
FML 8.28 8.44 0.16 1.93 
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2.3.1.5. Optimisation of mobile phase buffer concentration on Column B 
As shown in previous Sections 2.3.1.1, 2.3.1.2, 2.3.1.3 and 2.3.1.4, mobile 
phase pH, column temperature and gradient time were investigated. In this section the 
effect of buffer concentration was investigated. Buffer concentration usually has only a 
minor effect on relative retention of ionic samples for separations at low pH on modern 
(type-B) alkylsilica columns. However, for separations at pH > 6, protonated bases can 
be retained by ion exchange as a result of interaction with ionised silanols of silica-
based column packings. Ion-exchange retention decreases as mobile phase ionic 
strength increases, with the result that an increase in buffer concentration will tend to 
decrease the retention of protonated bases [25].  
The effect of ammonium acetate buffer concentration on the separation was 
investigated in the range between 5 and 45 mmol L
-1 
as shown
 
below in Figure 2.14.  
 
Figure 2.14: The effect of mobile phase buffer concentration on the separation of the 9 drug 
substances at (a) 45 mmol L
-1
, (b) 15 mmol L
-1
 and (c) 5 mmol L
-1 
ammonium acetate buffer,      
pH  9.9. Mobile phase B: 100% ACN. Column B. Gradient program: 0-10 minutes (15-50%). 
Flow rate: of 0.4 mL min
-1
. Column temperature: 30 °C. Injection volume: 5 µL. Detection:       
254 nm. Peaks: (1) OFL, (2) BMT, (3) KET, (4) FBP, (5) POH, (6) TIM, (7) BUN, (8) DEX, 
and (9) FML.  
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There was no significant influence of the buffer concentration on the separation 
of the drug substances, except for BUN/DEX, OFL/BMT and FBP/POH. At 5 and               
15 mmol L
-1
, baseline resolution for BUN/DEX (RS: 1.3) was not achieved, whereas at    
45 mmol L
-1
, the resolution between BUN/DEX was 2.7. A plot of buffer 
concentration versus resolution is shown below in Figure 2.15. Resolution between 
BUN/DEX was highest at 45 mmol L
-1 
(RS: 2.7),
 
however
 
the resolution between 
OFL/BMT (RS: 3.2) was the lowest at this buffer concentration and highest at 5 mmol 
L
-1 
(RS: 5.1), as shown in Figure 2.15. As the buffer concentration increased from 5 to 
45 mmol L
-1
,
 
the resolution of FBP/POH decreased from 9.4 to 5.5, respectively as 
shown below. However, the resolution of FBP/POH meets the desired resolution of        
≥ 2.0 at all buffer concentration variations. 
 
Figure 2.15: Plot of buffer concentration of the mobile phase versus resolution between 
OFL/BMT, POH/FBP and BUN/DEX. 
In terms of retention, an increase in buffer concentration caused a decrease in 
retention for BMT, BUN, and TIM as these drug substances are protonated bases 
under the conditions used in these experiments. There was little or no effect on the 
retention of DEX, POH, and FML as these are neutral compounds and are generally 
not affected by buffer concentration in RP-HPLC. And finally, for OFL, FBP, and 
KET, there was an increase in retention as the buffer concentration increased as these 
are weakly acidic drug substances. Overall, the buffer concentration at 45 mmol L
-1 
achieved
 
the best separation.  
0 10 20 30 40 50
0
2
4
6
8
10
12
Buffer Concentration mmol L-1 
Resolution 
Plot of Buffer Conc. vs Resolution 
Rs OFL/BMT
Rs FBP/POH
Rs BUN/DEX
50 
 
2.3.1.6. Optimisation of mobile phase buffer concentration and pH using Minitab  
 To ensure method robustness, a DOE [31, 32] using Minitab was employed to 
define the parameters which affect the separation and resolution of the drug substances 
under investigation and to optimise each of those conditions. The purpose of the DOE 
was to generate a method which separates the drug substances as efficiently as possible 
within a robust design space. The method parameters which affect the separation were 
defined as: (1) mobile phase pH as shown from Section 2.3.1.1, 2.3.1.2, 2.3.1.4 and        
(2) buffer concentration of the mobile phase as shown from Section 2.3.1.5. A ten 
minute gradient time was considered optimum in order to elute the nine drug 
substances within ten minutes. 
A two level fractional factorial DOE using Minitab was applied to the UPLC 
process. Factorial experimental designs investigate the effects of several different 
factors by varying the factors simultaneously instead of changing only one factor at a 
time. Factorial designs allow estimation of the sensitivity to each factor and also the 
combined effect of two or more factors. A DOE approach using Dry Lab and Minitab 
are very similar in that they are both software packages used for method development 
optimization. For both Dry Lab and Minitab, a designed experiment is created to 
investigate the effects of input variables (factors) on the output variable (response). A 
series of chromatographic runs are carried out, and the collected data is used to 
determine the factors settings that give the optimal results. Dry Lab results are visually 
analyzed using a 2D color resolution map and 3D color resolution cube, whereas 
Minitab results are statistically analyzed using analytical and graphing tools. 
 For this DOE using Minitab, buffer concentration and mobile phase pH were 
identified as the input variables as discussed previously and resolution between 
OFL/BMT and BUN/DEX were examined as the output. The DOE parameters and 
resolution results for OFL/BMT and BUN/DEX are outlined in Table 2.9. Buffer 
concentrations of 25 to 55 mmol L
-1
 were chosen as the lowest and highest 
concentrations. As shown previously (Section 2.3.1.5), baseline resolution between 
BUN/DEX was not achieved at the low buffer concentrations of 5 and 15 mmol L
-1
. 
The highest buffer concentration used in Section 2.3.1.5 was 45 mmol L
-1
, so in order 
to optimise the buffer concentration in a broad design space, a high buffer 
concentration of 55 mmol L
-1 
and a lower buffer concentration of 25 mmol L
-1 
was 
chosen. Figure 2.12 shows a good separation, with resolution values of ≥ 2.0 and 
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tailing values of ≤ 2.0 for all drug substances at mobile phase pH 9.9, so for the DOE, 
a lower pH value of 9.7 and a higher pH value of 10.1 were chosen to examine the 
separation. 
 
Table 2.9: Two level fractional factorial DOE for separation of peak pairs (OFL/BMT) 
and (BUN/DEX). 
Run 
Order 
Mobile 
phase pH 
Buffer concentration of 
mobile phase 
(mmol L
-1
) 
Resolution 
OFL/BMT 
Resolution 
BUN/DEX 
1 9.7 25 3.35 5.24 
2 10.1 25 4.88 0.1 
3 9.7 55 2.06 6.90 
4 10.1 55 3.23 1.25 
5 5 9.9 40 3.10 3.46 
 
  
 To assess the impact of mobile phase pH and buffer concentration of the 
mobile phase on the resolution of OFL/BMT and BUN/DEX, a main effects plot6 and 
an interaction plot7 were generated, as shown in Figures 2.16 - 2.19. As shown from the 
main effects plot for OFL/BMT (Figure 2.16) buffer concentration has slightly bigger 
main effects on the resolution of OFL/BMT than the mobile phase pH. The opposite is 
shown for BUN/DEX (Figure 2.17), where mobile phase pH has a much bigger effect 
on resolution over buffer concentration. An interaction plot shows the impact that 
changing one factor has on the other factor. Because an interaction of one factor can 
magnify or diminish main effects, evaluating interactions is extremely important. The 
significant interaction between pH and buffer concentration shows up as two lines with 
similar slopes. Parallel lines in an interaction plot indicate no interaction between pH 
and buffer concentration. The resolution between OFL/BMT at 25 mmol L-1 buffer is 
greater than the resolution between OFL/BMT at 55 mmol L
-1 
buffer at  both pH 9.7 
pH 10.1 (Figure 2.18). The opposite is shown for BUN/DEX, where the resolution is 
highest at 55 mmol L
-1
 at both pH 9.7 and pH 10.1 (Figure 2.19). In order to get the 
                                                          
5
 The mobile phase pH 9.9, 40 mmol L
-1
 experiment is the centre point for the DOE. 
6
 Used in conjunction with an analysis of variance and design of experiments to examine differences 
among level means for one or more factors. A main effect is present when different levels of a factor 
affect the response differently. A main effects plot graphs the response mean for each factor level 
connected by a line. 
7
 When the effect of a one factor depends on the level of the other factor. An interaction plot is used to 
visualise possible interactions. 
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highest resolution between OFL/BMT and BUN/DEX, the results for both the main 
effects plot and the interaction plot suggest a mid-range pH of approximately pH 9.9 
and a buffer concentration of approximately 40 mmol L
-1
. 
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Figure 2.16: Main effects plot for the resolution between OFL/BMT using mobile phase pH 
and buffer concentration of the mobile phase as the factors. 
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Figure 2.17: Main effects plot for the resolution between BUN/DEX using mobile phase pH 
and buffer concentration of the mobile phase as the factors. 
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Figure 2.18: Interaction plot for the resolution between OFL/BMT using mobile phase pH 
and buffer concentration of the mobile phase as the factors. 
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Figure 2.19: Interaction plot for the resolution between BUN/DEX using mobile phase pH and 
buffer concentration of the mobile phase as the factors. 
 
 To enable an assessment of the method parameters simultaneously and allow 
for optimisation of the analytical method, an optimisation plot was utilised as shown in        
Figure 2.20. Using the data generated from the DOE, this tool allows the user to 
modify each parameter and assess its impact on the separation. Each point is modified 
so that it operates on a plateau of composite desirability8 ensuring that the method will 
operate within the centre of a design space while still maintaining optimal resolution. 
An RS of 1.5, 2.0 and 3.0 were input as the lower, target and upper values, respectively 
for both OFL/BMT and BUN/DEX. The optimisation plot indicates that to achieve 
resolution of approximately 3.1 between OFL/BMT and 3.4 between BUN/DEX, a 
mobile phase of approximately pH 9.9 and a buffer concentration of 40 mmol L
-1 
is 
required. The final parameters decided were a mobile phase pH of 9.85 and a buffer 
                                                          
8
 Assesses how well a combination of input variables satisfies the defined goals for the responses. 
Individual desirability (d) evaluates how the settings optimise a single response; composite desirability 
(D) evaluates how the settings optimise a set of responses overall. Desirability has a range of zero to 
one. One represents the ideal case; zero indicates that one or more responses are outside their acceptable 
limits.  
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concentration of 40 mmol L
-1
. As shown previously at pH 10.1 (Table 2.9), BUN/DEX 
co-elute, so to ensure method robustness, a slightly lower mobile phase pH of 9.85 was 
chosen. 
 
Cur
High
Low0.00000
D
Optimal
d = 0.00000
Targ: 2.0
Rs OFL/B
y = 3.10
d = 0.00000
Targ: 2.0
Rs BUN/D
y = 3.4710
0.00000
Desirability
Composite
25.0
55.0
9.70
10.10
Buffer CpH
9.9000 40.0
 
Figure 2.20: Optimisation plot for the resolution between OFL/BMT and BUN/DEX using 
mobile phase pH and buffer concentration of the mobile phase as the factors. 
 
 Figure 2.21 (a) shows the separation of the nine drug substances under the 
optimised conditions. It was concluded that a mobile phase of approximately pH 9.85 
and a high buffer concentration of 40 mmol L
-1 
gave the
 
optimal separation in terms of 
retention, resolution, and tailing. As it can be seen, the nine drug substances are well 
separated from each other and all drug substances have tailing of ≤ 2.0 and resolution 
of ≥ 2.0. The resolution of OFL/BMT is 4.3 and resolution for BUN/DEX is 8.8.            
Figure 2.21 (b) shows the same chromatogram ran at 295 nm, the wavelength which 
was used for quantitation of OFL, KET and TIM which are shown in the figure 
enclosed in parentheses. 
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Figure 2.21: Final optimised chromatographic conditions for the separation of 9 selected drug 
substances at (a) 254 nm and (b) 295 nm. Column B: Waters Acquity Charged Surface Hybrid 
(CSH) C18 1.7 µm, 2.1 mm x 100 mm column. Mobile phase A: 40 mmol L
-1
 ammonium 
acetate buffer (pH 9.85), mobile phase B: 40 mmol L
-1 
ammonium acetate buffer (pH 
9.85)/ACN (50/50, v/v) Gradient program: 0-10 minutes (15-50% B), with a 3 minute 
equilibration time. Flow rate: 0.4 mL min
-1
. Column temperature:  30 °C. Injection volume: 5 
µL. Peaks: (1) OFL, (2) BMT, (3) KET, (4) FBP, (5) POH, (6) TIM, (7) BUN, (8) DEX, and 
(9) FML. 
2.3.1.7. Optimisation of injection volume 
During development of the chromatographic conditions, an injection volume of 
5 µL was used. However, in order to meet the limits of quantitation that were required 
for the cleaning method, an injection volume of 30 µL was considered suitable. All 
method validation criteria were met as shown in Section 2.3.2. In addition, an injection 
volume of 30 µL was used for all swab sampling studies in Chapter 3. 
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2.3.2. Method validation  
Note: The PAC standard (containing the impurities P17-AC and HAC) was injected 
separately for the method validation due to co-elution issues as discussed in Section 
2.3.1.3. Furthermore, PAC contains POH, so for quantitation purposes, the PAC was 
run on separate injections. 
The validation data for the analytical method is shown in Table 2.10 and the results are 
discussed below from Section 2.3.2.1 to Section 2.3.2.4. 
2.3.2.1. Linearity  
The linear range of the method was examined using standard solutions of the 
ten drug substances. Each drug substance was prepared at seven different 
concentrations (n=7) and injected in duplicate. The method provided linear standard 
curves (r
2
 > 0.999) for each drug substance of interest over a wide concentration range 
(Table 2.10). 
2.3.2.2. Precision 
A standard solution of the ten drug substances was injected six times for testing 
peak area, retention time and concentration precision, resulting in % RSD values of          
< 2.0% for all drug substances. The same standard solution was prepared and tested by 
a single analyst on different days, to establish Day-to-Day precision (equivalency)9. 
The ratio of drug substance concentration Day 2 versus drug substance concentration 
Day 1 was measured and the % RSD values were < 2.0% for all drug substances as 
listed in Table 2.10. 
2.3.2.3. Limit of Quantitation and Recoveries 
 The limit of quantitation limit (LOQ) of each drug substance was determined 
by recovery data and by the R.S.D of recovery data using peaks areas of three (n=3) 
separate injections of standard solutions. An R.S.D of ≤ 10% for the LOQ 
concentration and a recovery of 80-120% were achieved for all drug substances. OFL 
is linear from 0.10 to 10.0 µg/mL; however at 0.10 µg/mL the recovery of the OFL 
                                                          
9
 Ratio of drug substance concentration Day 2 versus drug substance concentration Day 1 
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solution was only 30%. The lowest OFL concentration to achieve a recovery of 80-
120% was 1.0 µg/mL. However, this quantitation limit is higher than the residue limit 
for an OFL swab sample as defined by Allergan Pharmaceuticals. For commercial 
reasons, this residue limit is proprietary information. 
2.3.2.4. Robustness  
 To evaluate the robustness of the analytical method, experimental conditions 
were deliberately altered to assess the effect of column temperature, flow rate, mobile 
phase buffer concentration, and mobile phase pH on the separation achieved. The 
column temperature was set to 30 ± 2 ⁰C, the mobile phase buffer concentration was 
varied from 40 ± 5 mmol L
-1
 ammonium acetate buffer, the pH of the mobile phase 
was varied from pH 9.85 ± 0.1, and a flow rate of 0.40 ± 0.04 mL min
-1
 was applied. 
For each condition investigated, three injections of the standard solution were injected 
to determine system suitability. For all parameters altered, a resolution of ≥ 2.0 was 
maintained between all drug substances in the standard injections. All drug substances 
for each robustness test investigated were compared to the nominal conditions and the 
concentration results were found to be equivalent as shown in Table 2.10. There was 
no significant difference from nominal conditions for all the drug substances under the 
various robustness challenges indicating that the method is capable of withstanding 
small changes in the parameters whilst still retaining the robustness necessary for the 
QC laboratory.  
59 
 
Table 2.10: Analytical performance criteria for the determination of ten drug substances.  
Linearity DEX FML POH PAC KET FBP OFL TIM BUN BMT 
Linearity 
r2 (n=7) 
> 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 > 0.999 
Linear Range 
(µg/mL) 
0.01-10.0 0.01-10.0 0.01-10.0 0.01-10.0 0.02-10.0 0.01-10.0 0.1-10.0 0.03-10.0 0.03-10.0 0.02-10.0 
Equation of the 
line 
y = 56439x -
236.8 
y = 130841x - 
534.5 
y = 163863x -
1007.7 
y = 148651x + 
536.8 
y = 94119x + 
66.9 
y = 265272 + 
24.6 
y= 85075x - 
15161 
y = 92771x - 
2744.9 
y = 119839x - 
895.0 
y = 212523x - 
436.3 
Limits of 
Quantitation
a
 
DEX FML POH PAC KET FBP OFL TIM BUN BMT 
LOQ µg/mL 0.01 0.01 0.01 0.01 0.02 0.01 1.0 0.03 0.03 0.02 
% Recovery  
(at LOQ) 
105 108 107 108 103 101 81 95 94 85 
% Recovery 
RSD  
0.5 1.8 0.0 1.3 1.3 1.5 1.7 4.1 3.5 5.2 
Precision
b
 
(%RSD) 
Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 Day-1 Day-2 
Retention time  0.21 0.02 0.19 0.01 0.24 0.02 0.03 0.00 0.43 0.02 0.25 0.03 0.07 0.23 0.22 0.02 0.21 0.02 0.40 0.02 
Area  0.67 0.06 0.93 0.13 0.47 0.09 0.07 0.03 0.30 0.11 0.42 0.14 1.12 0.98 0.29 0.14 0.25 0.24 0.14 0.14 
Concentration  0.19 0.09 0.29 0.09 0.17 0.06 0.13 0.06 0.17 0.08 0.28 0.08 1.05 0.65 0.38 0.32 0.63 0.28 1.08 0.38 
Equivalency
c
 1.01 1.01 1.00 1.00 1.02 0.99 0.98 1.01 1.01 1.03 
Robustness
d
 DEX FML POH PAC KET FBP OFL TIM BUN BMT 
Temperature: 
28 oC 
1.00 1.00 1.00 0.99 0.99 0.99 0.99 0.99 1.00 0.99 
Temperature: 
32 oC  
0.98 1.00 1.00 0.99 0.99 0.99 0.99 1.00 1.00 0.99 
 
60 
 
Table 2.10: (continued) 
Robustness
d
 DEX FML POH PAC KET FBP OFL TIM BUN BMT 
Flow: 0.36 mL 
min-1 
1.00 0.98 1.00 0.99 0.99 0.99 0.99 0.99 1.00 0.99 
Flow: 0.44 mL 
min-1 
1.00 1.00 0.99 0.99 0.99 0.99 0.99 1.00 1.00 0.99 
Buffer Conc: 
35mmol L-1 
0.99 1.00 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 
Buffer Conc: 
45mmol L-1 
1.00 1.00 1.00 0.99 0.99 0.99 0.99 1.00 1.00 0.99 
Mobile phase 
pH: 9.75 
1.00 1.00 1.00 0.99 0.99 0.99 0.99 0.99 1.00 0.99 
Mobile phase 
pH: 9.95 
0.99 1.00 0.99 0.99 0.99 0.99 0.99 0.99 1.00 0.99 
a
 n=3 
b
 n=6 
c
 Ratio of drug substance concentration Day 2 versus drug substance concentration Day 1 
d
 Ratio of drug substance concentration versus drug substance concentration under optimum (nominal) conditions 
 
 
 
    
 
 61 
 
2.4. Conclusion 
 A relatively rapid, robust UPLC method was developed for the determination 
and quantitation of up to ten drug substances (dexamethasone, fluorometholone, 
prednisolone acetate prednisolone, ketorolac tromethamine, flurbiprofen, timolol 
maleate, levobunolol hydrochloride, brimonidine tartrate and ofloxacin) 
simultaneously which can be used to verify that production equipment surfaces have 
been cleaned to an extent that meets existing regulatory requirements. Prednisolone 
acetate was validated on a separate injection due to co-elution issues. Standard 
analytical performance criteria were used for evaluation purposes, and the method was 
found to be both linear and precise, with LOQs meeting the requirements for analysis 
of  DEX, FML, POH, PAC, KET, FBP, TIM, BUN and BMT trace residues. This 
work demonstrates for the first time a single UPLC method directly applicable for 
analysis of a range of APIs simultaneously and provides the pharmaceutical industry 
with a robust analytical cleaning method with broad applicability. 
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Chapter 3 
 
Development of Swab Sampling Methodology in Support of 
Cleaning Validation 
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3.1. Introduction 
The aim of the developed swab sampling procedure described in this Chapter 
was to demonstrate that the selected drug substance residues could be adequately 
removed and quantitated from various product-contacting surfaces that included 
stainless steel, glass, teflon, and silicone. The analytical cleaning method that was 
developed and validated in Chapter 2 was used in combination with the developed 
swab sampling methodology described in this Chapter to verify that adequate removal 
of the drug substance residues from the various product contacting surfaces was 
achievable.  
There are many developed analytical methods and related swab sampling 
methodologies in the literature that describe the use of various product contacting 
surfaces, swabs and solvents. Polyester swabs are generally the most widely used 
swabs in pharmaceutical industries [1-3], however cotton swabs [4-6] are also used 
depending on the drug substance and recovery values obtained from the swab sampling 
analysis. 
This Chapter describes a swab sampling procedure that enables the removal 
and quantitation of up to 9 drug substances from various product-contacting 
manufacturing equipment surfaces, which covers a broad range of ophthalmic 
solutions. Therefore, the swab sampling methodology has a broad applicability. 
Removal of the drug substances from the selected surfaces were evaluated using a 
variety of swabbing materials (foam, cotton, polyester), and different solvents etc. A 
Design of Experiments (DOE) approach utilising Minitab software was adopted to 
determine the most appropriate swab and solvent for the swab sampling methodology. 
Because the product-contacting surfaces on the manufacturing equipment trains 
consist mainly of stainless steel, stainless steel was the surface primarily used in 
optimizing the swab sampling conditions. Different swabs, extracting solvents and 
sampling techniques were investigated in this research to evaluate for recoveries of the 
APIs on the various surfaces whilst ensuring minimal interferences from the swabbing 
materials and the product contacting surfaces. 
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3.2. Experimental 
3.2.1. Reagents and materials 
 Reference materials, dexamethasone (DEX, 99.7%), prednisolone acetate 
(PAC, 99.4%), and fluoromethalone (FML, 99.7%) were purchased from Sanofi 
Aventis (Paris, France), levobunolol hydrochloride (BUN, 99.7%) and brimonidine 
tartrate (BMT, 99.9%) from Piramal Healthcare (Andhra Pradesh, India), timolol 
maleate (TIM, 99.9%) from PCAS Finland OY (Turka, Finland), ketorolac 
tromethamine (KET, 98.7%) from Recordati (Milan, Italy), ofloxacin (OFL, 99.7%) 
from Chemo (Madrid, Spain), prednisolone (POH, 98.5%) from Sigma Aldrich (St. 
Louis, Missouri, US), and flurbiprofen (FBP, 99.6%) from Aesica Pharmaceuticals 
Limited (Cramlington, UK). 
HPLC grade methanol (MeOH), acetonitrile (ACN), and ethanol (EtOH) were 
purchased from Labscan (Tallaght, Dublin, Ireland). All chemicals were used as 
received, without any further purification. Deionised water was obtained from a 
Millipore Milli-Q water purification unit (Millipore, Bedford, MA, USA). 
3.2.2. Instrumentation 
 The chromatographic separation performed was as described in Section 2.2.2 
using a Waters Acquity Charged Surface Hybrid (CSH) C18 (1.7 µm, 2.1 mm x 100 
mm) column (Waters, Santry, Dublin, Ireland) (Column B). The compounds analyzed 
in this section were BMT, FBP, PAC, POH, BUN, DEX and FML (254 nm), and KET, 
OFL, and TIM (295 nm). A Branson sonication bath model 8510 (Branson Ultrasonics 
Corporation, Danbury, USA) was used for dissolving the standard reference materials 
and swab samples, and the balance used was a Mettler Toledo model XS205 (Manson 
Technology, Dublin, Ireland). TX761 swabs (ITW Texipe, NJ, USA) were used to 
recover the drug substances from the coupons. The coupons used were 316 stainless 
steel, toughened borosilicate glass, teflon (PTFE, Polytetrafluoroethylene) and  
platinum cured silicone, FDA approved, all obtained from Globe Pharma, NJ, USA. 
Minitab software was used to predict the most appropriate swab and solvent for the 
swab sampling procedure. 
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3.2.3. Method 
The chromatographic analysis was performed on Column B using 40 mmol L
-1 
ammonium acetate buffer (pH 9.85, adjusted with ammonium hydroxide solution) as 
mobile phase A and 40 mmol L
-1 
ammonium acetate buffer (pH 9.85)/ACN            
(50/50, v/v) as mobile phase B. The gradient programme was a linear gradient from     
0-10 minutes (30-100% B), with a 3 minute column re-equilibration time
10
. The flow 
was set at 0.4 mL min
-1 
and the column temperature was maintained at 30 °C. The 
injection volume was 30 µL, with detection by UV at 254 nm for BMT, FBP, PAC, 
POH, BUN, DEX and FML, and 295 nm for OFL, KET and TIM.  
3.2.4. Swab standard solution preparation 
Stock standard solutions of BMT, KET, FBP, TIM, and BUN were prepared in 
deionised water; PAC, POH, OFL and DEX in MeOH:water (70:30, v/v); and FML in 
methanol, each at a concentration of 2500 µg/mL. The standards were stored in a 
refrigerator at 4 °C, for two weeks with no significant loss of API. Appropriate 
dilutions were made with MeOH to obtain solutions containing 2 µg/mL, 10 µg/mL 
and 50 µg/mL. 
3.2.5. Swab sample preparation 
3.2.5.1. Product contacting surface preparation  
The selected surfaces (25 cm
2
) of stainless steel, glass, teflon and silicone were 
cleaned and dried. 100 µL of the swab standard solution was applied onto the coupons 
as
 
shown in Figure 3.1 at the three concentration levels in triplicate to give theoretical 
concentrations of 0.2 µg/25 cm
2
, 1 µg/25 cm
2
 and 5 µg/25 cm
2
.
 
The coupons were 
allowed to dry before swabbing. The swabbing procedure was carried out as shown in 
Section 3.2.5.2 and Figure 3.2. 
 
 
                                                          
10
 3 minute column equilibration time; The column was washed for 3 minutes at the end of each 
chromatographic run with the same mobile phase composition as the start of the gradient. This step was 
employed to re-equilibrate the column back to the original conditions before each injection.  
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Figure 3.1: Application of the swab standard solution onto the coupons. 
3.2.5.2. Swabbing procedure 
 The region to be swabbed was defined. 
 The swab head was dampened with the selected extraction solvent. 
 As shown from Figure 3.1, Step 1 and Step 2, the product contact surface was 
swabbed with an overlapping pattern. The swab was flipped over and the step 
was repeated, passing the swab in a perpendicular direction. The product 
contact surface was swabbed with the entire swab head flat against the surface. 
 The above swabbing process was repeated with a second swab at a 45° angle as 
shown in Step 3, Figure 3.2. The swab was flipped over and the step was 
repeated, passing the swab in a perpendicular direction (step 4). 
 The swab heads was cut, placed into a sample vial and sonicated for 5 minutes 
to extract the residue. 
 The extracted sample was transferred to a HPLC vial for analysis. 
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Figure 3.2: Swabbing procedure, taken from [10]. 
3.3. Results and discussion 
3.3.1. Optimisation of swab sampling methodology 
The surface of a manufacturing equipment line consists of mainly (>95%) 
stainless steel, but there are critical surfaces, which are made of teflon (PTFE, 
Polytetrafluoroethylene), glass, and silicone. The desired criteria were minimal 
interferences from the swab, stainless steel, glass, teflon and silicone surfaces. 
Sampling recoveries of ≥ 70% with an RSD value of ≤ 15% were the desired criteria, 
but swab sampling recoveries of ≥ 50% with an RSD value of ≤ 15% were deemed 
acceptable for the selected APIs (BMT, OFL, TIM, BUN, POH, DEX, KET, PAC, 
FML and FBP), as a correction factor will be applied to correct for the true amount of 
residue present on the manufacturing equipment surfaces as discussed in Chapter 1, 
Section 1.4.4.2. 
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3.3.1.1. Swab interferences 
One of the most widely used types of swab material for cleaning validation is a 
polyester swab. Polyester swabs generally offer high absorbency of residues, ultra- low 
particulates, and minimal extractable interferences [7-10]. Several different swabs 
were analysed to determine the level of particulates and extractable interferences as 
shown in Figure 3.3. 
 
Figure 3.3: The comparison of interferences from different types of swabs overlaid with a 
standard containing the nine drug substances: (a) (1) OFL, (2) BMT, (3) KET, (4) FBP, (5) 
POH, (6) TIM, (7) BUN, (8) DEX, and (FML), (b) a foam swab, (c) a cotton swab, (d) a 
TX761 polyester swab and (e) a constix SP-3 polyester swab. 
3.3.1.1.1. Impact of interferences from swab 
To determine the impact of particulates and extractable interferences from the 
swab, several different types of swabs were placed into 5 mL of water, sonicated for          
5 minutes and analysed by UPLC. The effect of particulates and extractable 
interferences from each swab is shown in Figure 3.3. The swabs with the least amount 
of particulates and extractable interferences were the polyester swabs; TX761 (d), and 
the constix swab (e). However, as can be seen from Figure 3.3, there is a potential 
interference from the TX761 (d) and Constix (e) swab at approximately 5.8 minutes.  
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3.3.1.2. Optimisation of swab sampling methodology using Minitab 
As shown previously from Figure 3.3, the polyester swabs; TX761 and the 
Constix SP-3 swab showed the least amount of particulates and extractable 
interferences. Therefore, these two swabs were evaluated for recoveries for the ten 
APIs on stainless steel surfaces using Minitab. As described previously in Chapter 2, a 
two level fractional factorial Design of Experiments (DOE) was used to investigate 
several different factors simultaneously instead of changing only one factor at a time. 
The other factors investigated were the use of 1 swab/2 swabs and solvent type (ACN 
and MeOH). A standard solution (BMT, OFL, TIM, BUN, POH, DEX, KET, FML, 
FBP, and a separate solution containing PAC) was applied onto stainless steel coupons 
to give a theoretical concentration of 0.2 µg/25 cm
2
. The coupons were swabbed with 
one/two Constix/Texwipe swabs with either ACN or MeOH as the swabbing solvent. 
The swabs were placed in 5 mL of deionised water and sonicated for five minutes. The 
DOE parameters are outlined in Table 3.1. 
   Table 3.1: Two level fractional factorial DOE for swab recoveries on stainless steel. 
Run Order No. Swabs Swab Type Solvent 
1 1 Texwipe TX761 ACN 
2 2 Texwipe TX761 ACN 
3 1 Constix SP-3 ACN 
4 2 Constix SP-3 ACN 
5  1 Texwipe TX761 MeOH 
6 2 Texwipe TX761 MeOH 
7 1 Constix SP-3 MeOH 
8 2 Constix SP-3 MeOH 
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Figure 3.4: Main effects plot for PAC, DEX, POH and FML % recoveries on stainless steel 
using number of swabs, type of swab and type of solvent as the factors. 
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Figure 3.5: Main effects plot for KET, TIM, BMT and OFL % recoveries on stainless steel 
using number of swabs, type of swab and type of solvent as the factors. 
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Figure 3.6: Main effects plot for FBP and BUN % recoveries on stainless steel using number 
of swabs, type of swab and type of solvent as the factors. 
The impact of the various factors on the % recoveries of the selected APIs from 
stainless steel was assessed by a main effects plot as shown in Figures 3.4 - 3.6. As 
shown from the main effects plots, the use of 2 tex-wipe TX761 swabs using methanol 
as the swabbing solvent gave the best recoveries for the stainless steel surface. The 
recoveries of OFL from all the different runs however were only ≤ 30%. However, this 
was not surprising as 0.2 µg/swab equates to 0.04 µg/mL, after dilution (5 mL) which 
is below the LOQ of the analytical method for OFL
11
. 
 Removal of the APIs from glass, teflon and silicone were evaluated using the 
optimised parameters from the Minitab experiment. Recoveries were acceptable for 
glass and teflon (≥ 50%) at 0.2 µg/25 cm2 for all drug substances, but only DEX, POH, 
PAC, FML, BMT, and KET met the target of ≥ 50% for the silicone surface, as shown 
in Table 3.2. TIM, BUN and FBP did not meet the target acceptance criteria of ≥ 50% 
as outlined in Table 3.2. Optimisation of the drug substance recoveries from the  
silicone surface is described in Section 3.3.1.3.  
 
                                                          
11
 The swab recoveries of OFL were not sufficient at 0.2 µg/25 cm
2
, and as mentioned in Chapter 2, the 
limit of quantitation of the analytical method is higher than the residue limit for an OFL swab as defined 
by Allergan Pharmaceuticals. Therefore, no further recovery work for OFL was carried out 
simultaneously with the other selected drug substances. 
 
 76 
 
3.3.1.3. Optimisation of swab recoveries on silicone surfaces 
As mentioned above BUN, FBP, and TIM did not the acceptance criteria of       
≥ 50% recovery from the silicone product-contacting surfaces. Therefore, ethanol and 
isopropanol were investigated as alternative solvents for the removal of the selected 
APIs from the silicone surfaces. The API swab standard solution was applied onto the 
silicone surface at 0.2 µg/swab and was swabbed as per swabbing procedure in Section 
3.2.5.2.  
        Table 3.2: Swab recoveries from silicone surfaces. 
API % recovery 
using methanol 
% recovery 
using ethanol 
% recovery using 
isopropanol 
BMT  
 
61.8 
 
64.6 63.4 
BUN  
 
31.9 61.1 
 
42.9 
DEX  
 
71.1 
 
74.7 
 
70.9 
FBP  
 
28.0 
 
33.3 28.8 
FML  
 
71.6 
 
82.2 80.8 
POH  
 
95.4 
 
95.4 95.4 
PAC 73.5 76.9 75.6 
KET  
 
64.1 71.1 64.2 
TIM  
 
23.5 
 
51.3 
 
33.3 
 
3.3.1.3.1. Impact of methanol on recoveries from silicone surfaces 
 The impact of using methanol to recover the selected APIs from silicone was 
evaluated and the results show that BMT, DEX, FML, POH, PAC, and KET can be 
recovered to an acceptable level (≥ 50%). However, the results show that BUN, FBP 
and TIM obtained recoveries of approximately 20-30% which is not an acceptable 
amount to recover, as per regulatory standards. 
3.3.1.3.2. Impact of isopropanol on recoveries from silicone surfaces 
 The results from using isopropanol to recover the APIs from the silicone 
surfaces are quite similar to the methanol results. Again, BUN, FBP and TIM did not 
achieve the ≥ 50% criterion, however the recoveries for BUN and TIM were 
approximately 10% higher, but the recovery of FBP remained the same (28%). 
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3.3.1.3.3. Impact of ethanol on recoveries from silicone surfaces 
 As shown from Table 3.2, using ethanol to recover the APIs from the silicone 
surfaces achieved the best results overall. BMT, BUN, DEX, FML, POH, PAC, KET, 
and TIM all obtained recovery values of ≥ 50% which was deemed as an acceptable 
result. However, FBP still only obtained recoveries of approximately 30% using 
ethanol.  
3.3.1.3.4 Impact of ethanol, methanol and isopropanol on recoveries of FBP from             
silicone surfaces 
Recoveries of ≥ 50%  for FBP were not achievable from the silicone surfaces 
at 0.2 µg/25 cm
2
 using methanol, ethanol or isopropanol. Therefore, an additional 
study was carried out where a standard solution was prepared containing FBP only. 
The standard containing only FBP was applied to the silicone surface at 0.2 µg/25 cm
2
 
and swabbed as before using ethanol. Ethanol was the solvent chosen as it gave the 
best recoveries overall for the removal of the selected APIs from the silicone surfaces 
and ethanol also gave slightly higher recoveries for FBP over methanol or isopropanol. 
The result achieved from this analysis was 51%, which just meets the ≥ 50% criterion.  
3.3.1.4. Discussion of silicone surface recovery results 
 The results from Section 3.3.1.3 show that certain APIs are more difficult to 
remove from silicone than other product contacting surfaces. As shown, the steroids 
(PAC, POH, DEX and FML) are more easily recovered from the silicone surfaces than 
the salt based APIs (BUN, TIM, BMT). It is interesting to note that the TIM, BUN, 
and BMT are more water soluble than the steroids and most all the drug substances are 
‘slightly soluble’ in alcohol according to USP solubility descriptions.  
 According to USP solubility descriptions, FBP is ‘freely soluble’ in dehydrated 
alcohol (ethanol), but this drug substance showed the lowest recovery values from 
silicone than the other drug substances. FBP is relatively non polar as it is ‘sparingly 
soluble’ in water, therefore it may have been more tightly bound to the nonpolar 
silicone surface than some of the other drug substances. It can be difficult to predict 
what APIs will be easily recovered or more difficult to recover from certain surfaces 
such as silicone as discussed below. 
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One example of insufficient recoveries obtained from silicone for certain drug 
substances is from a paper regarding a UPLC method and related swab sampling 
methodology that was developed for a range of steroids in a hormone pilot plant. The 
surfaces that were evaluated in this research were stainless steel, plexi-glass, teflon, 
textile and silicone. Recoveries of ≥ 70% were achieved for the seven steroids for 
stainless steel, plexi-glass, teflon and textile. However, only three of the steroids 
achieved recoveries of ≥ 70% from the silicone surface. Three of the steroids did not 
exceed the value of 70% (50-70%) and one steroid obtained a value of ≤ 50%. 
Additional studies were performed investigating the use of a variety of solvents that 
included methanol, acetonitrile and ethanol. However, the use of these solvents did not 
increase the recoveries of the problematic steroids [11]. 
Another study was conducted where recovery results were evaluated from a 
series of tests and showed that different materials of construction could be grouped 
into five different categories based on recovery performance, taking into account 
factors such as swab material, material of construction, solvent type, residue solubility, 
and sampling technique. These grouping however could not be correlated to the 
product contacting surface properties, e.g. different types of plastic were noted in the 
five different groupings. One point mentioned in the article is that for materials such as 
neoprene, EDPM, latex or silicone, the transport of compounds through these materials 
occurs more rapidly. It is also noted that the recovery of a selected API on a particular 
product contacting surface cannot be predicted. In order to predict the recovery 
outcome of the API from the surface, specific measurements of the fundamental 
transport properties from the solvents, APIs and materials of construction would have 
to be evaluated [12-13]. 
3.3.1.5. Interferences from the TX761 swab and selected surfaces 
 As shown from Figure 3.3, there is a potential interference near the retention 
time of POH from the TX761 swab. The chromatogram below shows the swab 
standard solution swabbed from stainless steel, glass, teflon and silicone using the 
TX761 swab, as well as the standard solution just spiked onto the TX761 swab. The 
only potentially interfering peak is at approximately 5.6 minutes with a resolution of 
1.3 between the peak originating from the TX761 swab and the POH peak. This does 
not interfere with the quantitation of POH. 
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Figure 3.7: The comparison of interferences from the selected surfaces and the TX761 swab; 
(a) silicone, (b) teflon, (c) glass, (d) stainless steel, (e) TX761, (1) OFL, (2) BMT, (3) KET, (4) 
FBP, (5) POH, (6) TIM, (7) BUN, (8) DEX, and (FML). 
3.3.2. Swab sampling validation 
3.3.2.1. Specificity 
Specificity was determined by demonstrating that the swabs and stainless steel, 
glass, teflon and silicone surfaces did not interfere with the quantitation of BMT, 
BUN, DEX, FBP, FML, POH, PAC (254 nm), and KET, and TIM (295 nm). To show 
that the determination of the drug substance residues were selective and free from any 
interferences, blank extractions of the swab material and blank swabs from the 
stainless steel, glass, teflon and silicone surfaces were injected. There were no 
interferences at the retention times of BMT, BUN, DEX, FBP, FML, POH, PAC      
(254 nm), and KET, and TIM (295 nm) that affected the recovery of the APIs from the 
selected surfaces. Therefore, the method can be considered as a specific method for 
these ten drug substances. 
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3.3.2.2. Accuracy (Swab sampling recovery studies) 
The nine drug substances were spiked onto and sampled from stainless steel, 
glass, teflon and silicone at 3 different concentrations (0.2 µg/25 cm
2
, 1.0 µg/25 cm
2 
and 5.0 µg/25 cm
2
) and accuracy was determined by the recovery data. The overall 
recovery (n=9) for each drug substance was calculated and the results are shown in 
Table 3.3. Overall recovery values of ≥ 70% were achieved for all drug substances on 
stainless steel, glass and teflon. For the silicone surface, FBP, TIM and BUN 
recoveries did not exceed 70%. However, the overall recoveries of these three drug 
substances were ≥ 50%, which meets regulatory standards.  
3.3.2.3. Precision 
Precision was established by the % RSD values of the accuracy recovery data 
(n=9) for each drug substance on each sampling surface. All % RSD values were           
≤ 15% for the nine drug substances for stainless steel, glass, teflon and silicone as 
listed in Table 3.3.  
3.3.2.4. Swab sample stability  
The stability of the swab sample solutions (spiked and swabbed from stainless 
steel, glass, teflon and silicone) were studied at a concentration of 1.0 µg/swab for 
BMT, BUN, DEX, FBP, FML, POH, PAC, KET, and TIM. The sample solutions were 
stored in a sample compartment and were chromatographed five times within a 20 hour 
period. For each surface investigated, two injections of the swab sample solution were 
injected at 0, 5, 10, 15 and 20 hours. All drug substances for each time point 
investigated were compared to the 0 hour time point and the ratio of mean results were 
calculated. The sample solutions proved to be stable for each drug substance within a 
20 hour period for all surfaces with ≤ 3% difference observed for each time point.  
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Table 3.3: Swab studies performance criteria for the determination of nine drug substances  
Parameters DEX FML POH PAC KET FBP TIM BUN BMT 
Specificity
a
  Pass Pass Pass Pass Pass Pass Pass Pass Pass 
Accuracy
b
 DEX FML POH PAC KET FBP TIM BUN BMT 
Steel 84.7 83.4 103.1 70.7 86.8 85.6 82.2 76.8 86.3 
Glass 86.8 83.4 100.2 84.4 80.4 86.2 83.1 78.7 78.2 
Teflon 79.0 76.4 98.9 73.4 73.0 84.2 78.7 75.6 73.3 
Silicone 81.1 70.8 98.1 78.8 77.9 52.5 67.8 69.5 84.8 
Precision
c
 DEX FML POH PAC KET FBP TIM BUN BMT 
Steel 3.3 5.1 2.5 9.6 2.9 2.3 10.2 13.9 3.9 
Glass 4.3 9.1 4.4 13.2 13.2 3.4 9.4 8.3 10.2 
Teflon 3.6 10.6 2.0 12.2 12.7 2.2 5.7 10.3 10.5 
Silicone 6.8 10.1 6.5 6.9 3.0 12.7 10.8 7.7 8.6 
Swab Sample
d
 
stability 
DEX FML POH PAC KET FBP TIM BUN BMT 
Steel 0.99 0.99 1.00 0.99 0.99 0.99 1.01 0.97 0.99 
Glass 1.01 1.00 1.00 0.99 1.00 1.00 1.00 1.00 1.00 
Teflon 1.00 1.00 1.00 0.99 1.00 1.00 1.02 0.98 1.00 
Silicone 1.00 1.00 1.00 0.99 1.00 1.00 0.99 0.98 1.00 
a The method is specific as there are no interferences from the stainless steel, glass, teflon and silicone, and TX761 swab that interfere with the quantitation of the drug substances 
b Calculated n=9 on overall recovery for each drug substance 
c Relative standard deviation (R.S.D.) of recovery data (n=9) 
d Ratio of drug substance concentration at 20 hours versus drug substance concentration at 0 hours
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3.4. Conclusion 
A swab sampling methodology was developed in combination with the 
analytical UPLC method that was developed in Chapter 2 to show that trace levels of 
API residues can be effectively removed from the selected surfaces on the 
manufacturing equipment. The swab sampling methodology was found to be specific, 
precise and accurate as per guidances and regulations. The swab sampling recovery 
results show a recovery of ≥ 70% for the selected APIs on stainless steel, glass and 
teflon. An overall recovery of ≥ 70% was achieved for DEX, FML, PAC, POH, KET 
and BMT for silicone and a recovery of between 50 and 70% was achieved for BUN, 
FBP and TIM which meets regulatory standards. However, the recovery values 
obtained for the removal of FBP from silicone surfaces were approximately 50%. In a 
situation where the recoveries obtained are ≤ 50%, it is advised to apply these silicone 
surfaces, i.e. gaskets, as dedicated parts of the manufacturing equipment. 
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In recent years, increased emphasis has been placed in pharmaceutical 
companies for implementing robust validated cleaning procedures. The cleaning 
procedure is one of the most important tasks to avoid contamination and cross-
contamination of APIs in pharmaceutical products manufactured on the same 
equipment trains. The cleaning procedures must be supported by appropriate analytical 
methods and related sampling methodologies. The cleaning analytical methods and 
related sampling methodologies are critical in establishing quality validated cleaning 
programs, as they quantitatively determine the amount of residual API, if present, on 
the manufacturing equipment post-cleaning. Therefore, the aim of this project was to 
develop and validate a robust cleaning analytical method and related sampling 
methodologies for the determination and quantitation of up to ten APIs in ophthalmic 
solutions. The challenge was to chromatographically separate up to 10 different drug 
substances which were a mixture of acidic, basic and neutral drug substances. In 
addition, the sampling methodologies were a critical aspect of the project. Several 
different product contacting surfaces were evaluated to determine whether the API 
residues could be adequately removed from the surfaces whilst ensuring minimal 
interferences from the swab and manufacturing equipment surfaces. 
The results in Chapter 2 show the development of a relatively rapid and robust 
UPLC method for the determination and quantitation of nine drug substances 
simultaneously. The APIs were efficiently separated on a C18 charged surface hybrid 
column (CSH) with sub-2 µm particles. The method was run at a low flow rate, thus 
using small amounts of mobile phase. Standard analytical performance criteria were 
used for evaluation purposes, and the method was found to be both linear (r
2
 > 0.999) 
and precise (%RSD < 2.0%), with LOQs as low as 0.01 µg/mL. 
The results in Chapter 3 show the development of a robust swab sampling 
procedure for the adequate removal of nine API residues from various product 
contacting manufacturing surfaces including stainless steel, silicone, glass and teflon. 
The APIs were sufficiently removed using methanol as the swabbing solvent for 
stainless steel, glass and teflon and ethanol was chosen for the removal of the various 
APIs from the silicone surfaces. The swab chosen for this was the TX761 polyester 
swab which also proved to be the swab with the least amount of interferences and 
extractables that may interfere with the analysis of the selected APIs. The swab 
sampling methodology was found to be both accurate and precise with recoveries of     
≥ 50% for all surfaces with RSD values of ≤ 15% which meet regulatory standards. 
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However, it has been shown that flurbiprofen was more difficult to remove 
from the silicone surfaces than the other APIs. The surfaces of most manufacturing 
equipment trains consist of mainly stainless steel, but there are surfaces such as gaskets 
or transfer line pipes that are made from silicone. These critical surfaces that cannot 
achieve a recovery of ≥ 50% during the swab sampling studies should become 
dedicated pieces of equipment to the production of the formulation containing the 
problematic API. 
Future work could involve an examination of the removal of problematic APIs 
from critical surfaces on the manufacturing equipment trains such as silicone. 
 
